BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Arzumanyan A, Reis HM, Feitelson MA. Pathogenic mechanisms in HBV- and HCV-associated hepatocellular carcinoma. Nat Rev Cancer. 2013;13:123-135. [PMID: 23344543 DOI: 10.1038/nrc3449] [Cited by in Crossref: 505] [Cited by in F6Publishing: 466] [Article Influence: 63.1] [Reference Citation Analysis]
Number Citing Articles
1 Li YS, Xie Q, Yang DY, Zheng Y. Role of RASSF1A promoter methylation in the pathogenesis of hepatocellular carcinoma: a meta-analysis of 21 cohort studies. Mol Biol Rep 2014;41:3925-33. [PMID: 24566681 DOI: 10.1007/s11033-014-3260-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
2 Dong CF, Xiao J, Shan LB, Li HY, Xiong YJ, Yang GL, Liu J, Yao SM, Li SX, Le XH, Yuan J, Zhou BP, Tipoe GL, Liu YX. Combined acoustic radiation force impulse, aminotransferase to platelet ratio index and Forns index assessment for hepatic fibrosis grading in hepatitis B. World J Hepatol. 2016;8:616-624. [PMID: 27190578 DOI: 10.4254/wjh.v8.i14.616] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
3 Wang K. Molecular mechanisms of hepatic apoptosis. Cell Death Dis. 2014;5:e996. [PMID: 24434519 DOI: 10.1038/cddis.2013.499] [Cited by in Crossref: 165] [Cited by in F6Publishing: 152] [Article Influence: 23.6] [Reference Citation Analysis]
4 Liu Y, Jin J, Ji J, Gao XM, Fan YC. Tumor necrosis factor-α-induced protein 8-like 2 mRNA in peripheral blood mononuclear cells is associated with the disease progression of chronic hepatitis B virus infection. Virol J 2019;16:120. [PMID: 31661000 DOI: 10.1186/s12985-019-1224-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
5 Chen MC, Huang HH, Lai CY, Lin YJ, Liou JP, Lai MJ, Li YH, Teng CM, Yang CR. Novel histone deacetylase inhibitor MPT0G009 induces cell apoptosis and synergistic anticancer activity with tumor necrosis factor-related apoptosis-inducing ligand against human hepatocellular carcinoma. Oncotarget 2016;7:402-17. [PMID: 26587975 DOI: 10.18632/oncotarget.6352] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 2.6] [Reference Citation Analysis]
6 Pavlović N, Heindryckx F. Targeting ER stress in the hepatic tumor microenvironment. FEBS J 2021. [PMID: 34331743 DOI: 10.1111/febs.16145] [Reference Citation Analysis]
7 El-Shamy A, Hotta H. Impact of hepatitis C virus heterogeneity on interferon sensitivity: an overview. World J Gastroenterol. 2014;20:7555-7569. [PMID: 24976696 DOI: 10.3748/wjg.v20.i24.7555] [Cited by in CrossRef: 29] [Cited by in F6Publishing: 24] [Article Influence: 4.8] [Reference Citation Analysis]
8 Xue S, Yang H, Qiao J, Pu F, Jiang J, Hubbard K, Hekmatyar K, Langley J, Salarian M, Long RC, Bryant RG, Hu XP, Grossniklaus HE, Liu ZR, Yang JJ. Protein MRI contrast agent with unprecedented metal selectivity and sensitivity for liver cancer imaging. Proc Natl Acad Sci U S A 2015;112:6607-12. [PMID: 25971726 DOI: 10.1073/pnas.1423021112] [Cited by in Crossref: 48] [Cited by in F6Publishing: 36] [Article Influence: 8.0] [Reference Citation Analysis]
9 Mirzaei H, Faghihloo E. Viruses as key modulators of the TGF-β pathway; a double-edged sword involved in cancer. Rev Med Virol 2018;28. [PMID: 29345394 DOI: 10.1002/rmv.1967] [Cited by in Crossref: 21] [Cited by in F6Publishing: 11] [Article Influence: 7.0] [Reference Citation Analysis]
10 Goto K, Kato N. MICA SNPs and the NKG2D system in virus-induced HCC. J Gastroenterol. 2015;50:261-272. [PMID: 25270965 DOI: 10.1007/s00535-014-1000-9] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 4.6] [Reference Citation Analysis]
11 Read SA, Douglas MW. Virus induced inflammation and cancer development. Cancer Lett 2014;345:174-81. [PMID: 23941825 DOI: 10.1016/j.canlet.2013.07.030] [Cited by in Crossref: 37] [Cited by in F6Publishing: 36] [Article Influence: 4.6] [Reference Citation Analysis]
12 Wei XL, Qiu MZ, Jin Y, Huang YX, Wang RY, Chen WW, Wang DS, Wang F, Luo HY, Zhang DS, Wang FH, Li YH, Xu RH. Hepatitis B virus infection is associated with gastric cancer in China: an endemic area of both diseases. Br J Cancer 2015;112:1283-90. [PMID: 25695484 DOI: 10.1038/bjc.2014.406] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 5.3] [Reference Citation Analysis]
13 Shi X, Liu J, Liu Q, Li M. IFI16 mis-localization can be a contributing factor to hepatocellular carcinoma progression. Med Hypotheses 2014;82:398-400. [PMID: 24491427 DOI: 10.1016/j.mehy.2014.01.017] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
14 Song Y, Li L, Ou Y, Gao Z, Li E, Li X, Zhang W, Wang J, Xu L, Zhou Y, Ma X, Liu L, Zhao Z, Huang X, Fan J, Dong L, Chen G, Ma L, Yang J, Chen L, He M, Li M, Zhuang X, Huang K, Qiu K, Yin G, Guo G, Feng Q, Chen P, Wu Z, Wu J, Zhao J, Luo L, Fu M, Xu B, Chen B, Li Y, Tong T, Wang M, Liu Z, Lin D, Zhang X, Yang H, Zhan Q. Identification of genomic alterations in oesophageal squamous cell cancer. Nature. 2014;509:91-95. [PMID: 24670651 DOI: 10.1038/nature13176] [Cited by in Crossref: 555] [Cited by in F6Publishing: 514] [Article Influence: 79.3] [Reference Citation Analysis]
15 Gotlieb N, Tachlytski I, Lapidot Y, Sultan M, Safran M, Ben-Ari Z. Hepatitis B virus downregulates vitamin D receptor levels in hepatoma cell lines, thereby preventing vitamin D-dependent inhibition of viral transcription and production. Mol Med. 2018;24:53. [PMID: 30326825 DOI: 10.1186/s10020-018-0055-0] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
16 Papatheodoridis GV, Chan HL, Hansen BE, Janssen HL, Lampertico P. Risk of hepatocellular carcinoma in chronic hepatitis B: assessment and modification with current antiviral therapy. J Hepatol. 2015;62:956-967. [PMID: 25595883 DOI: 10.1016/j.jhep.2015.01.002] [Cited by in Crossref: 247] [Cited by in F6Publishing: 233] [Article Influence: 41.2] [Reference Citation Analysis]
17 Yoon JY, Lee JJ, Gu S, Jung ME, Cho HS, Lim JH, Jun SY, Ahn JH, Min JS, Choi MH, Jeon SJ, Lee YJ, Go A, Heo YJ, Jung CR, Choi G, Lee K, Jeon MK, Kim NS. Novel indazole-based small compounds enhance TRAIL-induced apoptosis by inhibiting the MKK7-TIPRL interaction in hepatocellular carcinoma. Oncotarget 2017;8:112610-22. [PMID: 29348850 DOI: 10.18632/oncotarget.22614] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
18 Liao Y, Yuan S, Chen X, Zhu P, Li J, Qin L, Liao W. Up-regulation of BRCA1-associated RING Domain 1 Promotes Hepatocellular Carcinoma Progression by Targeting Akt Signaling. Sci Rep 2017;7:7649. [PMID: 28794477 DOI: 10.1038/s41598-017-07962-7] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
19 Jayachandran A, Dhungel B, Steel JC. Epithelial-to-mesenchymal plasticity of cancer stem cells: therapeutic targets in hepatocellular carcinoma. J Hematol Oncol. 2016;9:74. [PMID: 27578206 DOI: 10.1186/s13045-016-0307-9] [Cited by in Crossref: 88] [Cited by in F6Publishing: 86] [Article Influence: 17.6] [Reference Citation Analysis]
20 Tarocchi M, Galli A. Oxidative Stress as a Mechanism for Hepatocellular Carcinoma. Liver Pathophysiology. Elsevier; 2017. pp. 279-87. [DOI: 10.1016/b978-0-12-804274-8.00021-7] [Cited by in Crossref: 3] [Article Influence: 0.8] [Reference Citation Analysis]
21 Vescovo T, Refolo G, Vitagliano G, Fimia GM, Piacentini M. Molecular mechanisms of hepatitis C virus-induced hepatocellular carcinoma. Clin Microbiol Infect. 2016;22:853-861. [PMID: 27476823 DOI: 10.1016/j.cmi.2016.07.019] [Cited by in Crossref: 73] [Cited by in F6Publishing: 60] [Article Influence: 14.6] [Reference Citation Analysis]
22 Giraldo NA, Becht E, Vano Y, Sautès-fridman C, Fridman WH. The immune response in cancer: from immunology to pathology to immunotherapy. Virchows Arch 2015;467:127-35. [DOI: 10.1007/s00428-015-1787-7] [Cited by in Crossref: 35] [Cited by in F6Publishing: 29] [Article Influence: 5.8] [Reference Citation Analysis]
23 Li Y, Li M, Jia W, Ni Y, Chen T. MCEE: a data preprocessing approach for metabolic confounding effect elimination. Anal Bioanal Chem 2018;410:2689-99. [DOI: 10.1007/s00216-018-0947-4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
24 Villain P, Gonzalez P, Almonte M, Franceschi S, Dillner J, Anttila A, Park JY, De Vuyst H, Herrero R. European Code against Cancer 4th Edition: Infections and Cancer. Cancer Epidemiology 2015;39:S120-38. [DOI: 10.1016/j.canep.2015.10.006] [Cited by in Crossref: 24] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
25 Shwetha S, Gouthamchandra K, Chandra M, Ravishankar B, Khaja MN, Das S. Circulating miRNA profile in HCV infected serum: novel insight into pathogenesis. Sci Rep. 2013;3:1555. [PMID: 23549102 DOI: 10.1038/srep01555] [Cited by in Crossref: 59] [Cited by in F6Publishing: 57] [Article Influence: 7.4] [Reference Citation Analysis]
26 Park KU, Seo Y, Lee Y, Park J, Hwang I, Kang KJ, Nam J, Kim S, Kim JY. Altered microRNA expression profile in hepatitis B virus-related hepatocellular carcinoma. Gene 2015;573:278-84. [DOI: 10.1016/j.gene.2015.07.053] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
27 Selitsky SR, Baran-Gale J, Honda M, Yamane D, Masaki T, Fannin EE, Guerra B, Shirasaki T, Shimakami T, Kaneko S, Lanford RE, Lemon SM, Sethupathy P. Small tRNA-derived RNAs are increased and more abundant than microRNAs in chronic hepatitis B and C. Sci Rep 2015;5:7675. [PMID: 25567797 DOI: 10.1038/srep07675] [Cited by in Crossref: 84] [Cited by in F6Publishing: 70] [Article Influence: 14.0] [Reference Citation Analysis]
28 Du X, Meng F, Peng D, Wang Z, Ouyang W, Han Y, Gu Y, Fan L, Wu F, Jiang X, Xu F, Qin FX. Noncanonical Role of FBXO6 in Regulating Antiviral Immunity. J Immunol 2019;203:1012-20. [PMID: 31308089 DOI: 10.4049/jimmunol.1801557] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 3.5] [Reference Citation Analysis]
29 Murata M, Piao JS, Narahara S, Kawano T, Hamano N, Kang JH, Asai D, Ugawa R, Hashizume M. Expression and characterization of myristoylated preS1-conjugated nanocages for targeted cell delivery. Protein Expr Purif. 2015;110:52-56. [PMID: 25497224 DOI: 10.1016/j.pep.2014.12.001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
30 Cai ZX, Chen G, Zeng YY, Dong XQ, Lin MJ, Huang XH, Zhang D, Liu XL, Liu JF. Circulating tumor DNA profiling reveals clonal evolution and real-time disease progression in advanced hepatocellular carcinoma. Int J Cancer. 2017;141:977-985. [PMID: 28543104 DOI: 10.1002/ijc.30798] [Cited by in Crossref: 38] [Cited by in F6Publishing: 39] [Article Influence: 9.5] [Reference Citation Analysis]
31 Lebossé F, Zoulim F. [Hepatitis B vaccine and liver cancer]. Bull Cancer 2021;108:90-101. [PMID: 33358507 DOI: 10.1016/j.bulcan.2020.10.014] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
32 Li X, Zhang D, Guan S, Ye W, Liu L, Lou L. Efficacy of anti-VEGF agents in the treatment of elderly hepatocellular carcinoma: a systematic review. Oncotarget 2017;8:93179-85. [PMID: 29190987 DOI: 10.18632/oncotarget.21452] [Reference Citation Analysis]
33 Qu LS, Zhou GX. Significance of viral status on occurrence of hepatitis B-related hepatocellular carcinoma. World J Gastroenterol 2014;20:5999-6005. [PMID: 24876722 DOI: 10.3748/wjg.v20.i20.5999] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
34 Li W, Ma Y, Guo Z, Xing R, Liu Z. Efficient Screening of Glycan-Specific Aptamers Using a Glycosylated Peptide as a Scaffold. Anal Chem 2021;93:956-63. [PMID: 33300777 DOI: 10.1021/acs.analchem.0c03675] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
35 Feng J, Wu L, Ji J, Chen K, Yu Q, Zhang J, Chen J, Mao Y, Wang F, Dai W, Xu L, Wu J, Guo C. PKM2 is the target of proanthocyanidin B2 during the inhibition of hepatocellular carcinoma. J Exp Clin Cancer Res 2019;38:204. [PMID: 31101057 DOI: 10.1186/s13046-019-1194-z] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 12.0] [Reference Citation Analysis]
36 Zhang MH, Shen QH, Qin ZM, Wang QL, Chen X. Systematic tracking of disrupted modules identifies significant genes and pathways in hepatocellular carcinoma. Oncol Lett 2016;12:3285-95. [PMID: 27899995 DOI: 10.3892/ol.2016.5039] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
37 Weidle UH, Schmid D, Birzele F, Brinkmann U. MicroRNAs Involved in Metastasis of Hepatocellular Carcinoma: Target Candidates, Functionality and Efficacy in Animal Models and Prognostic Relevance. Cancer Genomics Proteomics 2020;17:1-21. [PMID: 31882547 DOI: 10.21873/cgp.20163] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 8.0] [Reference Citation Analysis]
38 Zheng X, Lu F, Xu X, Zhang L. Extended chain conformation of β-glucan and its effect on antitumor activity. J Mater Chem B 2017;5:5623-31. [DOI: 10.1039/c7tb01324h] [Cited by in Crossref: 22] [Article Influence: 5.5] [Reference Citation Analysis]
39 Niemeyer DJ, Simo KA, Iannitti DA, McKillop IH. Ablation therapy for hepatocellular carcinoma: past, present and future perspectives. Hepat Oncol 2014;1:67-79. [PMID: 30190942 DOI: 10.2217/hep.13.8] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
40 Plissonnier ML, Herzog K, Levrero M, Zeisel MB. Non-Coding RNAs and Hepatitis C Virus-Induced Hepatocellular Carcinoma. Viruses. 2018;10. [PMID: 30380697 DOI: 10.3390/v10110591] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 5.3] [Reference Citation Analysis]
41 Su Z, Li Y, Liao Y, Cai B, Chen J, Zhang J, Li L, Ying B, Tao C, Wang L. Association of the gene polymorphisms in sodium taurocholate cotransporting polypeptide with the outcomes of hepatitis B infection in Chinese Han population. Infect Genet Evol 2014;27:77-82. [PMID: 25010264 DOI: 10.1016/j.meegid.2014.07.001] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.4] [Reference Citation Analysis]
42 Lei T, Ling X. IGF-1 promotes the growth and metastasis of hepatocellular carcinoma via the inhibition of proteasome-mediated cathepsin B degradation. World J Gastroenterol 2015;21:10137-49. [PMID: 26401078 DOI: 10.3748/wjg.v21.i35.10137] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 17] [Article Influence: 3.6] [Reference Citation Analysis]
43 Zona L, Tawar RG, Zeisel MB, Xiao F, Schuster C, Lupberger J, Baumert TF. CD81-receptor associations--impact for hepatitis C virus entry and antiviral therapies. Viruses 2014;6:875-92. [PMID: 24553110 DOI: 10.3390/v6020875] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 3.6] [Reference Citation Analysis]
44 van Zuylen WJ, Rawlinson WD, Ford CE. The Wnt pathway: a key network in cell signalling dysregulated by viruses. Rev Med Virol 2016;26:340-55. [PMID: 27273590 DOI: 10.1002/rmv.1892] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 4.8] [Reference Citation Analysis]
45 Zhu A, Liao X, Li S, Zhao H, Chen L, Xu M, Duan X. HBV cccDNA and Its Potential as a Therapeutic Target. J Clin Transl Hepatol 2019;7:258-62. [PMID: 31608218 DOI: 10.14218/JCTH.2018.00054] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
46 Yu X, Lian B, Wang L, Zhang Y, Dai E, Meng F, Liu D, Wang S, Liu X, Wang J, Li X, Jiang W. The pan-cancer analysis of gene expression patterns in the context of inflammation. Mol Biosyst 2014;10:2270-6. [PMID: 24958091 DOI: 10.1039/c4mb00258j] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.2] [Reference Citation Analysis]
47 Liu D, Staveley-O’Carroll KF, Li G. Immune-based Therapy Clinical Trials in Hepatocellular Carcinoma. J Clin Cell Immunol. 2015;6. [PMID: 26877890 DOI: 10.4172/2155-9899.1000376] [Cited by in Crossref: 8] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
48 Wu JJ, Yang Y, Peng WT, Sun JC, Sun WY, Wei W. G protein-coupled receptor kinase 2 regulating β2-adrenergic receptor signaling in M2-polarized macrophages contributes to hepatocellular carcinoma progression. Onco Targets Ther 2019;12:5499-513. [PMID: 31371988 DOI: 10.2147/OTT.S209291] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
49 Guo L, Wang D, Ouyang X, Tang N, Chen X, Zhang Y, Zhu H, Li X. Recent Advances in HBV Reactivation Research. Biomed Res Int. 2018;2018:2931402. [PMID: 30687740 DOI: 10.1155/2018/2931402] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
50 Giebel S, Boratyn-nowicka A, Karabon L, Jedynak A, Pamula-pilat J, Tecza K, Kula D, Kowal M, Frydecka I, Grzybowska E. Associations between genes for killer immunoglobulin-like receptors and their ligands in patients with epithelial ovarian cancer. Human Immunology 2014;75:508-13. [DOI: 10.1016/j.humimm.2014.04.002] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
51 Kanda M, Sugimoto H, Kodera Y. Genetic and epigenetic aspects of initiation and progression of hepatocellular carcinoma. World J Gastroenterol. 2015;21:10584-10597. [PMID: 26457018 DOI: 10.3748/wjg.v21.i37.10584] [Cited by in CrossRef: 37] [Cited by in F6Publishing: 41] [Article Influence: 7.4] [Reference Citation Analysis]
52 Liu T, Sun Q, Liu Y, Cen S, Zhang Q. The MOV10 helicase restricts hepatitis B virus replication by inhibiting viral reverse transcription. J Biol Chem 2019;294:19804-13. [PMID: 31722967 DOI: 10.1074/jbc.RA119.009435] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
53 Garozzo A, Falzone L, Rapisarda V, Marconi A, Cinà D, Fenga C, Spandidos DA, Libra M. The risk of HCV infection among health-care workers and its association with extrahepatic manifestations (Review). Mol Med Rep 2017;15:3336-9. [PMID: 28339065 DOI: 10.3892/mmr.2017.6378] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
54 Singh A, Shafi S, Upadhyay T, Najmi AK, Kohli K, Pottoo FH. Insights into Nanotherapeutic Strategies as an Impending Approach to Liver Cancer Treatment. Curr Top Med Chem 2020;20:1839-54. [PMID: 32579503 DOI: 10.2174/1568026620666200624161801] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
55 Woo HY, Yoo SY, Heo J. New chemical treatment options in second-line hepatocellular carcinoma: what to do when sorafenib fails? Expert Opin Pharmacother. 2017;18:35-44. [PMID: 27849399 DOI: 10.1080/14656566.2016.1261825] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 2.4] [Reference Citation Analysis]
56 Pollicino T, Saitta C. Occult hepatitis B virus and hepatocellular carcinoma. World J Gastroenterol. 2014;20:5951-5961. [PMID: 24876718 DOI: 10.3748/wjg.v20.i20.5951] [Cited by in CrossRef: 38] [Cited by in F6Publishing: 34] [Article Influence: 6.3] [Reference Citation Analysis]
57 Nelson Hayes C, Zhang P, Chayama K; Department of Gastroenterology and Metabolism, Graduate School of Biomedical & Health Sciences, Applied Life Sciences, Institute of Biomedical & Health Sciences, Hiroshima University, Minami-ku, Hiroshima, Japan, Department of Gastroenterology and Metabolism, Graduate School of Biomedical & Health Sciences, Applied Life Sciences, Institute of Biomedical & Health Sciences, Hiroshima University, Minami-ku, Hiroshima, Japan, Department of Gastroenterology and Metabolism, Graduate School of Biomedical & Health Sciences, Applied Life Sciences, Institute of Biomedical & Health Sciences, Hiroshima University, Minami-ku, Hiroshima, Japan. The Role of Lipids in Hepatocellular Carcinoma. In: Tirnitz-parker JE, editor. Hepatocellular Carcinoma. Codon Publications; 2019. pp. 95-110. [DOI: 10.15586/hepatocellularcarcinoma.2019.ch5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 3.5] [Reference Citation Analysis]
58 Yang X, Guo X, Chen Y, Chen G, Ma Y, Huang K, Zhang Y, Zhao Q, Winkler CA, An P. Telomerase reverse transcriptase promoter mutations in hepatitis B virus-associated hepatocellular carcinoma. Oncotarget. 2016;7:27838-27847. [PMID: 27056898 DOI: 10.18632/oncotarget.8539] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 4.8] [Reference Citation Analysis]
59 Wu Y, Liu Z, Xu X. Molecular subtyping of hepatocellular carcinoma: A step toward precision medicine. Cancer Commun (Lond) 2020;40:681-93. [PMID: 33290597 DOI: 10.1002/cac2.12115] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
60 Lai Y, Feng B, Abudoureyimu M, Zhi Y, Zhou H, Wang T, Chu X, Chen P, Wang R. Non-coding RNAs: Emerging Regulators of Sorafenib Resistance in Hepatocellular Carcinoma. Front Oncol 2019;9:1156. [PMID: 31750247 DOI: 10.3389/fonc.2019.01156] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
61 Zheng Y, Lv P, Wang S, Cai Q, Zhang B, Huo F. LncRNA PLAC2 upregulates p53 to induce hepatocellular carcinoma cell apoptosis. Gene 2019;712:143944. [PMID: 31233763 DOI: 10.1016/j.gene.2019.143944] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
62 Ng TI, Krishnan P, Pilot-Matias T, Kati W, Schnell G, Beyer J, Reisch T, Lu L, Dekhtyar T, Irvin M, Tripathi R, Maring C, Randolph JT, Wagner R, Collins C. In Vitro Antiviral Activity and Resistance Profile of the Next-Generation Hepatitis C Virus NS5A Inhibitor Pibrentasvir. Antimicrob Agents Chemother 2017;61:e02558-16. [PMID: 28193664 DOI: 10.1128/AAC.02558-16] [Cited by in Crossref: 89] [Cited by in F6Publishing: 37] [Article Influence: 22.3] [Reference Citation Analysis]
63 Ren L, Li C, Wang Y, Teng Y, Sun H, Xing B, Yang X, Jiang Y, He F. In Vivo Phosphoproteome Analysis Reveals Kinome Reprogramming in Hepatocellular Carcinoma. Mol Cell Proteomics 2018;17:1067-83. [PMID: 29472430 DOI: 10.1074/mcp.RA117.000421] [Cited by in Crossref: 13] [Cited by in F6Publishing: 6] [Article Influence: 4.3] [Reference Citation Analysis]
64 Tye H, Jenkins BJ. Tying the knot between cytokine and toll-like receptor signaling in gastrointestinal tract cancers. Cancer Sci. 2013;104:1139-1145. [PMID: 23710764 DOI: 10.1111/cas.12205] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 2.4] [Reference Citation Analysis]
65 Boltjes A, Movita D, Boonstra A, Woltman AM. The role of Kupffer cells in hepatitis B and hepatitis C virus infections. J Hepatol. 2014;61:660-671. [PMID: 24798624 DOI: 10.1016/j.jhep.2014.04.026] [Cited by in Crossref: 99] [Cited by in F6Publishing: 84] [Article Influence: 14.1] [Reference Citation Analysis]
66 Wu R, Zhang Y, Xiang Y, Tang Y, Cui F, Cao J, Zhou L, You Y, Duan L. Association between serum S100A9 levels and liver necroinflammation in chronic hepatitis B. J Transl Med 2018;16:83. [PMID: 29615081 DOI: 10.1186/s12967-018-1462-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
67 Jiang X, Wu J, Zhang Y, Wang S, Yu X, Li R, Huang X. MiR-613 functions as tumor suppressor in hepatocellular carcinoma by targeting YWHAZ. Gene 2018;659:168-74. [PMID: 29551505 DOI: 10.1016/j.gene.2018.03.036] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 5.3] [Reference Citation Analysis]
68 Cai N, Xie S, Qiu D, Jia C, Du C, Liu W, Chen J, Zhang Q. Potential effects of α-mangostin in the prevention and treatment of hepatocellular carcinoma. Journal of Functional Foods 2016;26:309-18. [DOI: 10.1016/j.jff.2016.08.014] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 1.6] [Reference Citation Analysis]
69 Herceg Z, Lambert MP, van Veldhoven K, Demetriou C, Vineis P, Smith MT, Straif K, Wild CP. Towards incorporating epigenetic mechanisms into carcinogen identification and evaluation. Carcinogenesis. 2013;34:1955-1967. [PMID: 23749751 DOI: 10.1093/carcin/bgt212] [Cited by in Crossref: 64] [Cited by in F6Publishing: 43] [Article Influence: 8.0] [Reference Citation Analysis]
70 Lu X, Zhou C, Li R, Liang Z, Zhai W, Zhao L, Zhang S. Critical role for the long non-coding RNA AFAP1-AS1 in the proliferation and metastasis of hepatocellular carcinoma. Tumour Biol 2016;37:9699-707. [PMID: 26803513 DOI: 10.1007/s13277-016-4858-8] [Cited by in Crossref: 35] [Cited by in F6Publishing: 39] [Article Influence: 7.0] [Reference Citation Analysis]
71 Wallace MC, Preen D, Jeffrey GP, Adams LA. The evolving epidemiology of hepatocellular carcinoma: a global perspective. Expert Rev Gastroenterol Hepatol. 2015;9:765-779. [PMID: 25827821 DOI: 10.1586/17474124.2015.1028363] [Cited by in Crossref: 181] [Cited by in F6Publishing: 163] [Article Influence: 30.2] [Reference Citation Analysis]
72 Kwon YC, Bose SK, Steele R, Meyer K, Di Bisceglie AM, Ray RB, Ray R. Promotion of Cancer Stem-Like Cell Properties in Hepatitis C Virus-Infected Hepatocytes. J Virol. 2015;89:11549-11556. [PMID: 26355082 DOI: 10.1128/jvi.01946-15] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 4.3] [Reference Citation Analysis]
73 Fang G, Wang J, Sun X, Xu R, Zhao X, Shao L, Sun C, Wang Y. LncRNA MAGI2-AS3 is downregulated in the distant recurrence of hepatocellular carcinoma after surgical resection and affects migration and invasion via ROCK2. Annals of Hepatology 2020;19:535-40. [DOI: 10.1016/j.aohep.2020.04.007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
74 Huang X, Young KH, Guo W, Wang Y, Wang X, Xi Y, Wang L, Bai O. Identification of hepatitis B virus aetiologic antigens, HBx and Pre-S2, in diffuse large B-cell lymphoma. J Viral Hepat 2020;27:948-50. [PMID: 32281709 DOI: 10.1111/jvh.13301] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
75 Liu Y, Zhou Y, Liu X, Dong F, Wang C, Wang Z. Wasserstein GAN-Based Small-Sample Augmentation for New-Generation Artificial Intelligence: A Case Study of Cancer-Staging Data in Biology. Engineering 2019;5:156-63. [DOI: 10.1016/j.eng.2018.11.018] [Cited by in Crossref: 32] [Cited by in F6Publishing: 8] [Article Influence: 16.0] [Reference Citation Analysis]
76 Yoo S, Wang W, Wang Q, Fiel MI, Lee E, Hiotis SP, Zhu J. A pilot systematic genomic comparison of recurrence risks of hepatitis B virus-associated hepatocellular carcinoma with low- and high-degree liver fibrosis. BMC Med 2017;15:214. [PMID: 29212479 DOI: 10.1186/s12916-017-0973-7] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 6.0] [Reference Citation Analysis]
77 Wang L, Yao M, Fang M, Zheng WJ, Dong ZZ, Pan LH, Zhang HJ, Yao DF. Expression of hepatic Wnt5a and its clinicopathological features in patients with hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int 2018;17:227-32. [PMID: 29709351 DOI: 10.1016/j.hbpd.2018.03.005] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
78 Liu J, Hua P, Hui L, Zhang LL, Hu Z, Zhu YW. Identification of hub genes and pathways associated with hepatocellular carcinoma based on network strategy. Exp Ther Med 2016;12:2109-19. [PMID: 27703495 DOI: 10.3892/etm.2016.3599] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
79 Hashimoto R, Kanda M, Takami H, Shimizu D, Oya H, Hibino S, Okamura Y, Yamada S, Fujii T, Nakayama G. Aberrant expression of melanoma-associated antigen-D2 serves as a prognostic indicator of hepatocellular carcinoma outcome following curative hepatectomy. Oncol Lett. 2015;9:1201-1206. [PMID: 25663882 DOI: 10.3892/ol.2014.2823] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
80 Yao M, Wang L, Yang J, Yan X, Cai Y, Yao D. IGF-I receptor as an emerging potential molecular-targeted for hepatocellular carcinoma in vitro and in vivo. Tumor Biol 2016;37:14677-86. [DOI: 10.1007/s13277-016-5296-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
81 Catamo E, Zupin L, Crovella S, Celsi F, Segat L. Non-classical MHC-I human leukocyte antigen (HLA-G) in hepatotropic viral infections and in hepatocellular carcinoma. Hum Immunol 2014;75:1225-31. [PMID: 25318079 DOI: 10.1016/j.humimm.2014.09.019] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
82 Liu Z, Dai X, Wang T, Zhang C, Zhang W, Zhang W, Zhang Q, Wu K, Liu F, Liu Y, Wu J. Hepatitis B virus PreS1 facilitates hepatocellular carcinoma development by promoting appearance and self-renewal of liver cancer stem cells. Cancer Lett 2017;400:149-60. [PMID: 28455240 DOI: 10.1016/j.canlet.2017.04.017] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 5.0] [Reference Citation Analysis]
83 Gu C, Tao S, Hu K, Ming L, Luo M, Guo H, Su Y, Liu J, Xie Y. Establishment of an in vitro reporter system for screening HBx-targeting molecules. Acta Biochim Biophys Sin (Shanghai) 2019;51:431-40. [PMID: 30811522 DOI: 10.1093/abbs/gmz016] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
84 Robinson KM, Dunning Hotopp JC. Mobile elements and viral integrations prompt considerations for bacterial DNA integration as a novel carcinogen. Cancer Lett 2014;352:137-44. [PMID: 24956175 DOI: 10.1016/j.canlet.2014.05.021] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
85 Cuninghame S, Jackson R, Zehbe I. Hypoxia-inducible factor 1 and its role in viral carcinogenesis. Virology. 2014;456-457:370-383. [PMID: 24698149 DOI: 10.1016/j.virol.2014.02.027] [Cited by in Crossref: 37] [Cited by in F6Publishing: 41] [Article Influence: 5.3] [Reference Citation Analysis]
86 Ringelhan M, McKeating JA, Protzer U. Viral hepatitis and liver cancer. Philos Trans R Soc Lond B Biol Sci. 2017;372. [PMID: 28893941 DOI: 10.1098/rstb.2016.0274] [Cited by in Crossref: 100] [Cited by in F6Publishing: 79] [Article Influence: 33.3] [Reference Citation Analysis]
87 Zhang C, Huang C, Sui X, Zhong X, Yang W, Hu X, Li Y. Association between gene methylation and HBV infection in hepatocellular carcinoma: A meta-analysis. J Cancer. 2019;10:6457-6465. [PMID: 31772678 DOI: 10.7150/jca.33005] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
88 Nault JC, Galle PR, Marquardt JU. The role of molecular enrichment on future therapies in hepatocellular carcinoma. J Hepatol. 2018;69:237-247. [PMID: 29505843 DOI: 10.1016/j.jhep.2018.02.016] [Cited by in Crossref: 50] [Cited by in F6Publishing: 44] [Article Influence: 16.7] [Reference Citation Analysis]
89 Kaibori M, Yoshii K, Yokota I, Hasegawa K, Nagashima F, Kubo S, Kon M, Izumi N, Kadoya M, Kudo M, Kumada T, Sakamoto M, Nakashima O, Matsuyama Y, Takayama T, Kokudo N. Impact of Advanced Age on Survival in Patients Undergoing Resection of Hepatocellular Carcinoma: Report of a Japanese Nationwide Survey. Annals of Surgery 2019;269:692-9. [DOI: 10.1097/sla.0000000000002526] [Cited by in Crossref: 33] [Cited by in F6Publishing: 13] [Article Influence: 16.5] [Reference Citation Analysis]
90 Luan Z, He Y, He F, Chen Z. Rocaglamide overcomes tumor necrosis factor-related apoptosis-inducing ligand resistance in hepatocellular carcinoma cells by attenuating the inhibition of caspase-8 through cellular FLICE-like-inhibitory protein downregulation. Mol Med Rep 2015;11:203-11. [PMID: 25333816 DOI: 10.3892/mmr.2014.2718] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
91 Atsama Amougou M, Marchio A, Bivigou-Mboumba B, Noah Noah D, Banai R, Atangana PJA, Fewou Moundipa P, Pineau P, Njouom R. Enrichment in selected genotypes, basal core and precore mutations of hepatitis B virus in patients with hepatocellular carcinoma in Cameroon. J Viral Hepat 2019;26:1086-93. [PMID: 31106515 DOI: 10.1111/jvh.13131] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
92 Tornesello ML, Buonaguro L, Tatangelo F, Botti G, Izzo F, Buonaguro FM. Mutations in TP53, CTNNB1 and PIK3CA genes in hepatocellular carcinoma associated with hepatitis B and hepatitis C virus infections. Genomics. 2013;102:74-83. [PMID: 23583669 DOI: 10.1016/j.ygeno.2013.04.001] [Cited by in Crossref: 89] [Cited by in F6Publishing: 79] [Article Influence: 11.1] [Reference Citation Analysis]
93 Wu L, Zhang X, Zhao Z, Wang L, Li B, Li G, Dean M, Yu Q, Wang Y, Lin X, Rao W, Mei Z, Li Y, Jiang R, Yang H, Li F, Xie G, Xu L, Wu K, Zhang J, Chen J, Wang T, Kristiansen K, Zhang X, Li Y, Yang H, Wang J, Hou Y, Xu X. Full-length single-cell RNA-seq applied to a viral human cancer: applications to HPV expression and splicing analysis in HeLa S3 cells. Gigascience 2015;4:51. [PMID: 26550473 DOI: 10.1186/s13742-015-0091-4] [Cited by in Crossref: 45] [Cited by in F6Publishing: 34] [Article Influence: 7.5] [Reference Citation Analysis]
94 Chen X, Bode AM, Dong Z, Cao Y. The epithelial–mesenchymal transition (EMT) is regulated by oncoviruses in cancer. FASEB j 2016;30:3001-10. [DOI: 10.1096/fj.201600388r] [Cited by in Crossref: 31] [Cited by in F6Publishing: 18] [Article Influence: 6.2] [Reference Citation Analysis]
95 Chen K, Shi W, Xin Z, Wang H, Zhu X, Wu X, Li Z, Li H, Liu Y. Replication of genome wide association studies on hepatocellular carcinoma susceptibility loci in a Chinese population. PLoS One. 2013;8:e77315. [PMID: 24204805 DOI: 10.1371/journal.pone.0077315] [Cited by in Crossref: 28] [Cited by in F6Publishing: 31] [Article Influence: 3.5] [Reference Citation Analysis]
96 Sun S, Osterman MD, Li M. Tissue specificity of DNA damage response and tumorigenesis. Cancer Biol Med 2019;16:396-414. [PMID: 31565474 DOI: 10.20892/j.issn.2095-3941.2019.0097] [Cited by in F6Publishing: 7] [Reference Citation Analysis]
97 Illiano P, Brambilla R, Parolini C. The mutual interplay of gut microbiota, diet and human disease. FEBS J 2019;287:833-55. [DOI: 10.1111/febs.15217] [Cited by in Crossref: 45] [Cited by in F6Publishing: 33] [Article Influence: 45.0] [Reference Citation Analysis]
98 Alves VA, Pinheiro C, Morais-Santos F, Felipe-Silva A, Longatto-Filho A, Baltazar F. Characterization of monocarboxylate transporter activity in hepatocellular carcinoma. World J Gastroenterol. 2014;20:11780-11787. [PMID: 25206282 DOI: 10.3748/wjg.v20.i33.11780] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.7] [Reference Citation Analysis]
99 Li QY, Zhao NM, Wang LC, Duan HF, Ma YC, Zhang W, Zhao HW, Qin YH. Individuals having variant genotypes of cytochrome P450 2C19 are at increased risk of developing primary liver cancer in Han populations, without infection with the hepatitis virus. Tumour Biol 2014;35:9023-6. [PMID: 24906606 DOI: 10.1007/s13277-014-2144-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
100 Kan F, Ye L, Yan T, Cao J, Zheng J, Li W. Proteomic and transcriptomic studies of HBV-associated liver fibrosis of an AAV-HBV-infected mouse model. BMC Genomics 2017;18:641. [PMID: 28830339 DOI: 10.1186/s12864-017-3984-z] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
101 Teng YC, Neo JC, Wu JC, Chen YF, Kao CH, Tsai TF. Expression of a hepatitis B virus pre-S2 deletion mutant in the liver results in hepatomegaly and hepatocellular carcinoma in mice. J Pathol 2017;241:463-74. [PMID: 27868197 DOI: 10.1002/path.4850] [Cited by in Crossref: 24] [Cited by in F6Publishing: 17] [Article Influence: 6.0] [Reference Citation Analysis]
102 Xie N, Yuan K, Zhou L, Wang K, Chen HN, Lei Y, Lan J, Pu Q, Gao W, Zhang L, Shen G, Li Q, Xiao H, Tang H, Xiang R, He M, Feng P, Nice EC, Wei Y, Zhang H, Yang J, Huang C. PRKAA/AMPK restricts HBV replication through promotion of autophagic degradation. Autophagy 2016;12:1507-20. [PMID: 27305174 DOI: 10.1080/15548627.2016.1191857] [Cited by in Crossref: 33] [Cited by in F6Publishing: 32] [Article Influence: 6.6] [Reference Citation Analysis]
103 Ohta K, Hoshino H, Wang J, Ono S, Iida Y, Hata K, Huang SK, Colquhoun S, Hoon DS. MicroRNA-93 activates c-Met/PI3K/Akt pathway activity in hepatocellular carcinoma by directly inhibiting PTEN and CDKN1A. Oncotarget. 2015;6:3211-3224. [PMID: 25633810 DOI: 10.18632/oncotarget.3085] [Cited by in Crossref: 101] [Cited by in F6Publishing: 95] [Article Influence: 20.2] [Reference Citation Analysis]
104 Qian Y, Li Y, Zheng C, Lu T, Sun R, Mao Y, Yu S, Fan H, Zhang Z. High methylation levels of histone H3 lysine 9 associated with activation of hypoxia-inducible factor 1α (HIF-1α) predict patients' worse prognosis in human hepatocellular carcinomas. Cancer Genet 2020;245:17-26. [PMID: 32534446 DOI: 10.1016/j.cancergen.2020.04.077] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
105 Zhang QY, Chu XY, Jiang LH, Liu MY, Mei ZL, Zhang HY. Identification of Non-Electrophilic Nrf2 Activators from Approved Drugs. Molecules 2017;22:E883. [PMID: 28587109 DOI: 10.3390/molecules22060883] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
106 Li HY, Luo F, Li XY, Fu XF, He JF, Tian YZ, Zhu JJ, Chu XY, Zhao HL. Inhibition of Polo-Like Kinase 1 by BI2536 Reverses the Multidrug Resistance of Human Hepatoma Cells In Vitro and In Vivo. Anticancer Agents Med Chem 2019;19:740-9. [PMID: 30836927 DOI: 10.2174/1871520619666190301145637] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
107 Song X, Tan S, Wu Z, Xu L, Wang Z, Xu Y, Wang T, Gao C, Gong Y, Liang X, Gao L, Spear BT, Ma C. HBV suppresses ZHX2 expression to promote proliferation of HCC through miR-155 activation. Int J Cancer 2018;143:3120-30. [PMID: 29752719 DOI: 10.1002/ijc.31595] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 7.3] [Reference Citation Analysis]
108 Yu Y, Li H, Zhang B, Pan X, Zhu X, Ding Y, Li G. Peptide network for detection of tissue-remodeling enzyme in the prognosis of hepatocellular carcinoma. ACS Appl Mater Interfaces 2015;7:4401-5. [PMID: 25629926 DOI: 10.1021/am5089378] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
109 Liu Y, Luo Y, Li X, Zheng W, Chen T. Rational Design of Selenadiazole Derivatives to Antagonize Hyperglycemia-Induced Drug Resistance in Cancer Cells. Chem Asian J 2015;10:642-52. [DOI: 10.1002/asia.201403409] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 4.8] [Reference Citation Analysis]
110 Wahyuni TS, Tumewu L, Permanasari AA, Apriani E, Adianti M, Rahman A, Widyawaruyanti A, Lusida MI, Fuad A, Soetjipto, Nasronudin, Fuchino H, Kawahara N, Shoji I, Deng L, Aoki C, Hotta H. Antiviral activities of Indonesian medicinal plants in the East Java region against hepatitis C virus. Virol J 2013;10:259. [PMID: 24089993 DOI: 10.1186/1743-422X-10-259] [Cited by in Crossref: 32] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
111 Diner BA, Lum KK, Cristea IM. The emerging role of nuclear viral DNA sensors. J Biol Chem. 2015;290:26412-26421. [PMID: 26354430 DOI: 10.1074/jbc.r115.652289] [Cited by in Crossref: 51] [Cited by in F6Publishing: 36] [Article Influence: 8.5] [Reference Citation Analysis]
112 Najafi Z, Sharifi M, Javadi G. Degradation of miR-21 induces apoptosis and inhibits cell proliferation in human hepatocellular carcinoma. Cancer Gene Ther 2015;22:530-5. [PMID: 26427512 DOI: 10.1038/cgt.2015.51] [Cited by in Crossref: 34] [Cited by in F6Publishing: 33] [Article Influence: 5.7] [Reference Citation Analysis]
113 Lu L, Zhou J, Shi J, Peng XJ, Qi XX, Wang Y, Li FY, Zhou FY, Liu L, Liu ZQ. Drug-Metabolizing Activity, Protein and Gene Expression of UDP-Glucuronosyltransferases Are Significantly Altered in Hepatocellular Carcinoma Patients. PLoS One 2015;10:e0127524. [PMID: 26010150 DOI: 10.1371/journal.pone.0127524] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
114 Xu G, Zhang L, Ma A, Qian Y, Ding Q, Liu Y, Wang B, Yang Z, Liu Y. SIP1 is a downstream effector of GADD45G in senescence induction and growth inhibition of liver tumor cells. Oncotarget 2015;6:33636-47. [PMID: 26378039 DOI: 10.18632/oncotarget.5602] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
115 Unfried JP, Fortes P. LncRNAs in HCV Infection and HCV-Related Liver Disease. Int J Mol Sci 2020;21:E2255. [PMID: 32214045 DOI: 10.3390/ijms21062255] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 13.0] [Reference Citation Analysis]
116 Luedde T, Kaplowitz N, Schwabe RF. Cell death and cell death responses in liver disease: mechanisms and clinical relevance. Gastroenterology. 2014;147:765-783.e4. [PMID: 25046161 DOI: 10.1053/j.gastro.2014.07.018] [Cited by in Crossref: 365] [Cited by in F6Publishing: 333] [Article Influence: 52.1] [Reference Citation Analysis]
117 Podlaha O, Wu G, Downie B, Ramamurthy R, Gaggar A, Subramanian M, Ye Z, Jiang Z. Genomic modeling of hepatitis B virus integration frequency in the human genome. PLoS One 2019;14:e0220376. [PMID: 31356634 DOI: 10.1371/journal.pone.0220376] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 7.0] [Reference Citation Analysis]
118 Kaibori M, Matsushima H, Ishizaki M, Kosaka H, Matsui K, Kariya S, Yoshii K, Sekimoto M. The Impact of Sorafenib in Combination with Transarterial Chemoembolization on the Outcomes of Intermediate-Stage Hepatocellular Carcinoma. Asian Pac J Cancer Prev 2021;22:1217-24. [PMID: 33906315 DOI: 10.31557/APJCP.2021.22.4.1217] [Reference Citation Analysis]
119 Su Z, Li Y, Liao Y, Cai B, Chen J, Zhang J, Li L, Ying B, Tao C, Zhao M, Ba Z, Zhang Z, Wang L. Polymorphisms in sodium taurocholate cotransporting polypeptide are not associated with hepatitis B virus clearance in Chinese Tibetans and Uygurs. Infect Genet Evol 2016;41:128-34. [PMID: 27051045 DOI: 10.1016/j.meegid.2016.03.039] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
120 Bellizzi A, Ahye N, Jalagadugula G, Wollebo HS. A Broad Application of CRISPR Cas9 in Infectious Diseases of Central Nervous System. J Neuroimmune Pharmacol 2019;14:578-94. [PMID: 31512166 DOI: 10.1007/s11481-019-09878-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
121 Page AJ, Cosgrove DC, Philosophe B, Pawlik TM. Hepatocellular Carcinoma. Surgical Oncology Clinics of North America 2014;23:289-311. [DOI: 10.1016/j.soc.2013.10.006] [Cited by in Crossref: 40] [Cited by in F6Publishing: 36] [Article Influence: 5.7] [Reference Citation Analysis]
122 Qin X, Guo Y, Du H, Zhong Y, Zhang J, Li X, Yu H, Zhang Z, Jia Z, Li Z. Comparative Analysis for Glycopatterns and Complex-Type N-Glycans of Glycoprotein in Sera from Chronic Hepatitis B- and C-Infected Patients. Front Physiol 2017;8:596. [PMID: 28871230 DOI: 10.3389/fphys.2017.00596] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
123 Deng L, Gan X, Ito M, Chen M, Aly HH, Matsui C, Abe T, Watashi K, Wakita T, Suzuki T, Okamoto T, Matsuura Y, Mizokami M, Shoji I, Hotta H. Peroxiredoxin 1, a Novel HBx-Interacting Protein, Interacts with Exosome Component 5 and Negatively Regulates Hepatitis B Virus (HBV) Propagation through Degradation of HBV RNA. J Virol. 2019;93. [PMID: 30567989 DOI: 10.1128/jvi.02203-18] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
124 Tornesello ML, Buonaguro L, Izzo F, Buonaguro FM. Molecular alterations in hepatocellular carcinoma associated with hepatitis B and hepatitis C infections. Oncotarget. 2016;7:25087-25102. [PMID: 26943571 DOI: 10.18632/oncotarget.7837] [Cited by in Crossref: 38] [Cited by in F6Publishing: 36] [Article Influence: 12.7] [Reference Citation Analysis]
125 Cevik O, Li D, Baljinnyam E, Manvar D, Pimenta EM, Waris G, Barnes BJ, Kaushik-Basu N. Interferon regulatory factor 5 (IRF5) suppresses hepatitis C virus (HCV) replication and HCV-associated hepatocellular carcinoma. J Biol Chem 2017;292:21676-89. [PMID: 29079574 DOI: 10.1074/jbc.M117.792721] [Cited by in Crossref: 17] [Cited by in F6Publishing: 10] [Article Influence: 4.3] [Reference Citation Analysis]
126 Liu HH, Fang Y, Wang JW, Yuan XD, Fan YC, Gao S, Han LY, Wang K. Hypomethylation of the cyclin D1 promoter in hepatitis B virus-associated hepatocellular carcinoma. Medicine (Baltimore) 2020;99:e20326. [PMID: 32443384 DOI: 10.1097/MD.0000000000020326] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
127 Yuan H, Zhao L, Yuan Y, Yun H, Zheng W, Geng Y, Yang G, Wang Y, Zhao M, Zhang X. HBx represses WDR77 to enhance HBV replication by DDB1-mediated WDR77 degradation in the liver. Theranostics 2021;11:8362-78. [PMID: 34373747 DOI: 10.7150/thno.57531] [Reference Citation Analysis]
128 Tajiri K, Shimizu Y. New horizon for radical cure of chronic hepatitis B virus infection. World J Hepatol 2016;8:863-73. [PMID: 27478536 DOI: 10.4254/wjh.v8.i21.863] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
129 Li Q, Lu F, Deng G, Wang K. Modeling the effects of covalently closed circular DNA and dendritic cells in chronic HBV infection. Journal of Theoretical Biology 2014;357:1-9. [DOI: 10.1016/j.jtbi.2014.04.037] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
130 Xie K, Liu J, Chen J, Dong J, Ma H, Liu Y, Hu Z. Methylation-associated silencing of microRNA-34b in hepatocellular carcinoma cancer. Gene. 2014;543:101-107. [PMID: 24704024 DOI: 10.1016/j.gene.2014.03.059] [Cited by in Crossref: 38] [Cited by in F6Publishing: 41] [Article Influence: 5.4] [Reference Citation Analysis]
131 Zhang X, Zhai L, Rong C, Qin X, Li S. Association of Ghrelin Gene Polymorphisms and Serum Ghrelin Levels with the Risk of Hepatitis B Virus-Related Liver Diseases in a Chinese Population. PLoS One 2015;10:e0143069. [PMID: 26599409 DOI: 10.1371/journal.pone.0143069] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
132 Hu C, Huang K, Zhao L, Zhang F, Wu Z, Li L. Serum ammonia is a strong prognostic factor for patients with acute-on-chronic liver failure. Sci Rep. 2020;10:16970. [PMID: 33046732 DOI: 10.1038/s41598-020-73603-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
133 Tsai TH, Song E, Zhu R, Di Poto C, Wang M, Luo Y, Varghese RS, Tadesse MG, Ziada DH, Desai CS. LC-MS/MS-based serum proteomics for identification of candidate biomarkers for hepatocellular carcinoma. Proteomics. 2015;15:2369-2381. [PMID: 25778709 DOI: 10.1002/pmic.201400364] [Cited by in Crossref: 45] [Cited by in F6Publishing: 38] [Article Influence: 7.5] [Reference Citation Analysis]
134 Wang JH, Hu TH, Chen CH, Hung CH, Yen YH, Chang KC, Lu SN. Liver stiffness measurement at complete virological response in hepatoma prediction for HBV-related cirrhosis patient with potent antiviral agent. Kaohsiung J Med Sci. 2019;35:708-714. [PMID: 31430035 DOI: 10.1002/kjm2.12114] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
135 Jiang W, Yue S, He S, Chen C, Liu S, Jiang H, Tong H, Liu X, Wang J, Zhang F, Sun H, Li M, Wang C. New design of probe and central-homo primer pairs to improve TaqMan™ PCR accuracy for HBV detection. J Virol Methods 2018;254:25-30. [PMID: 29407210 DOI: 10.1016/j.jviromet.2018.01.008] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
136 Abdelrheem DA, Rahman AA, Elsayed KN, Abd El-mageed H, Mohamed HS, Ahmed SA. Isolation, characterization, in vitro anticancer activity, dft calculations, molecular docking, bioactivity score, drug-likeness and admet studies of eight phytoconstituents from brown alga sargassum platycarpum. Journal of Molecular Structure 2021;1225:129245. [DOI: 10.1016/j.molstruc.2020.129245] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
137 Santos P, Almeida F. Exosome-Based Vaccines: History, Current State, and Clinical Trials. Front Immunol 2021;12:711565. [PMID: 34335627 DOI: 10.3389/fimmu.2021.711565] [Reference Citation Analysis]
138 Raghunath A, Sundarraj K, Arfuso F, Sethi G, Perumal E. Dysregulation of Nrf2 in Hepatocellular Carcinoma: Role in Cancer Progression and Chemoresistance. Cancers (Basel) 2018;10:E481. [PMID: 30513925 DOI: 10.3390/cancers10120481] [Cited by in Crossref: 68] [Cited by in F6Publishing: 54] [Article Influence: 22.7] [Reference Citation Analysis]
139 Podlaha O, Gane E, Brunetto M, Fung S, Chuang WL, Pan CQ, Jiang Z, Liu Y, Bhardwaj N, Mukherjee P, Flaherty J, Gaggar A, Subramanian M, Izumi N, Shalimar, Lim YS, Marcellin P, Buti M, Chan HLY, Agarwal K. Large-scale viral genome analysis identifies novel clinical associations between hepatitis B virus and chronically infected patients. Sci Rep 2019;9:10529. [PMID: 31324819 DOI: 10.1038/s41598-019-46609-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
140 Bakr NM, Awad A, A Moustafa E. Association of genetic variants in the interleukin-18 gene promoter with risk of hepatocellular carcinoma and metastasis in patients with hepatitis C virus infection. IUBMB Life 2018;70:165-74. [PMID: 29341496 DOI: 10.1002/iub.1714] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
141 Zhang YQ, Guo JS. Antiviral therapies for hepatitis B virus-related hepatocellular carcinoma. World J Gastroenterol. 2015;21:3860-3866. [PMID: 25852270 DOI: 10.3748/wjg.v21.i13.3860] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
142 Li Z, Ma L, Di L, Lin X. MicroRNA‑1271‑5p alleviates the malignant development of hepatitis B virus‑mediated liver cancer via binding to AQP5. Mol Med Rep 2021;23:386. [PMID: 33760167 DOI: 10.3892/mmr.2021.12025] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
143 Ding Y, Liu K, Xu Y, Zhao Q, Lou S, Xiang X, Yan L, Cao Z, Xie Q, Zhu C, Bao S, Wang H. Combination of inflammatory score/liver function and AFP improves the diagnostic accuracy of HBV-related hepatocellular carcinoma. Cancer Med 2020;9:3057-69. [PMID: 32150664 DOI: 10.1002/cam4.2968] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
144 Li G, Staveley-O'Carroll KF, Kimchi ET. Potential of Radiofrequency Ablation in Combination with Immunotherapy in the Treatment of Hepatocellular Carcinoma. J Clin Trials. 2016;6. [PMID: 28042519 DOI: 10.4172/2167-0870.1000257] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
145 Katoh M. Multi‑layered prevention and treatment of chronic inflammation, organ fibrosis and cancer associated with canonical WNT/β‑catenin signaling activation (Review). Int J Mol Med 2018;42:713-25. [PMID: 29786110 DOI: 10.3892/ijmm.2018.3689] [Cited by in Crossref: 19] [Cited by in F6Publishing: 37] [Article Influence: 6.3] [Reference Citation Analysis]
146 Liu B, Yao Z, Hu K, Huang H, Xu S, Wang Q, Yang Y, Ren J. ShRNA-mediated silencing of the Ndc80 gene suppress cell proliferation and affected hepatitis B virus-related hepatocellular carcinoma. Clin Res Hepatol Gastroenterol. 2016;40:297-303. [PMID: 26382282 DOI: 10.1016/j.clinre.2015.08.002] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
147 Brass A, Brenndörfer ED. The role of chemokines in hepatitis C virus-mediated liver disease. Int J Mol Sci. 2014;15:4747-4779. [PMID: 24646914 DOI: 10.3390/ijms15034747] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
148 Tsai TH, Wang M, Di Poto C, Hu Y, Zhou S, Zhao Y, Varghese RS, Luo Y, Tadesse MG, Ziada DH, Desai CS, Shetty K, Mechref Y, Ressom HW. LC-MS profiling of N-Glycans derived from human serum samples for biomarker discovery in hepatocellular carcinoma. J Proteome Res 2014;13:4859-68. [PMID: 25077556 DOI: 10.1021/pr500460k] [Cited by in Crossref: 41] [Cited by in F6Publishing: 36] [Article Influence: 5.9] [Reference Citation Analysis]
149 Zhang J, Fan J, Zhou C, Qi Y. miR-363-5p as potential prognostic marker for hepatocellular carcinoma indicated by weighted co-expression network analysis of miRNAs and mRNA. BMC Gastroenterol 2017;17:81. [PMID: 28637446 DOI: 10.1186/s12876-017-0637-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
150 Sasaki R, Devhare P, Ray RB, Ray R. Hepatitis C virus-induced tumor-initiating cancer stem-like cells activate stromal fibroblasts in a xenograft tumor model. Hepatology 2017;66:1766-78. [PMID: 28664988 DOI: 10.1002/hep.29346] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
151 Jiang D, Deng J, Dong C, Ma X, Xiao Q, Zhou B, Yang C, Wei L, Conran C, Zheng SL, Ng IO, Yu L, Xu J, Sham PC, Qi X, Hou J, Ji Y, Cao G, Li M. Knowledge-based analyses reveal new candidate genes associated with risk of hepatitis B virus related hepatocellular carcinoma. BMC Cancer 2020;20:403. [PMID: 32393195 DOI: 10.1186/s12885-020-06842-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
152 Vlachogiannakos J, Papatheodoridis G. Hepatocellular carcinoma in chronic hepatitis B patients under antiviral therapy. World J Gastroenterol. 2013;19:8822-8830. [PMID: 24379605 DOI: 10.3748/wjg.v19.i47.8822] [Cited by in CrossRef: 29] [Cited by in F6Publishing: 27] [Article Influence: 4.1] [Reference Citation Analysis]
153 Khoo T, Lam D, Olynyk JK. Impact of modern antiviral therapy of chronic hepatitis B and C on clinical outcomes of liver disease. WJG 2021;27:4831-45. [DOI: 10.3748/wjg.v27.i29.4831] [Reference Citation Analysis]
154 Liu X, Zhang Y, Liu L, Pan Y, Hu Y, Yang P, Liao M. Protective and therapeutic effects of nanoliposomal quercetin on acute liver injury in rats. BMC Pharmacol Toxicol 2020;21:11. [PMID: 32059743 DOI: 10.1186/s40360-020-0388-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
155 Cheng S, Li T, Wang C, Wang K, Lai C, Yan J, Fan H, Sun F, Wang Z, Zhang P, Yu L, Hong Z, Lei G, Sun B, Gao Y, Xiao Z, Ji X, Wang R, Wu J, Wang X, Zhang S, Yang P. Decreased long intergenic noncoding RNA P7 predicts unfavorable prognosis and promotes tumor proliferation via the modulation of the STAT1-MAPK pathway in hepatocellular carcinoma. Oncotarget. 2018;9:36057-36066. [PMID: 30546827 DOI: 10.18632/oncotarget.23282] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
156 Shlomai A, de Jong YP, Rice CM. Virus associated malignancies: the role of viral hepatitis in hepatocellular carcinoma. Semin Cancer Biol. 2014;26:78-88. [PMID: 24457013 DOI: 10.1016/j.semcancer.2014.01.004] [Cited by in Crossref: 91] [Cited by in F6Publishing: 86] [Article Influence: 13.0] [Reference Citation Analysis]
157 Wang G, Liu Y, Qiu P, Zhou SF, Xu L, Wen P, Wen J, Xiao X. Cost-effectiveness analysis of lamivudine, telbivudine, and entecavir in treatment of chronic hepatitis B with adefovir dipivoxil resistance. Drug Des Devel Ther. 2015;9:2839-2846. [PMID: 26082614 DOI: 10.2147/dddt.s73150] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
158 Abraham JA, Golubnitschaja O. Time for paradigm change in management of hepatocellular carcinoma: is a personalized approach on the horizon? Per Med 2016;13:455-67. [PMID: 29767598 DOI: 10.2217/pme-2016-0013] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
159 Murakami Y, Tanahashi T, Okada R, Toyoda H, Kumada T, Enomoto M, Tamori A, Kawada N, Taguchi YH, Azuma T. Comparison of hepatocellular carcinoma miRNA expression profiling as evaluated by next generation sequencing and microarray. PLoS One. 2014;9:e106314. [PMID: 25215888 DOI: 10.1371/journal.pone.0106314] [Cited by in Crossref: 51] [Cited by in F6Publishing: 39] [Article Influence: 7.3] [Reference Citation Analysis]
160 Lee MH, Yang HI, Lu SN, Jen CL, You SL, Wang LY, L'Italien G, Chen CJ, Yuan Y;  REVEAL-HCV Study Group. Hepatitis C virus genotype 1b increases cumulative lifetime risk of hepatocellular carcinoma. Int J Cancer. 2014;135:1119-1126. [PMID: 24482200 DOI: 10.1002/ijc.28753] [Cited by in Crossref: 44] [Cited by in F6Publishing: 39] [Article Influence: 6.3] [Reference Citation Analysis]
161 Araujo OC, Barros JJ, do Ó KM, Nabuco LC, Luz CA, Perez RM, Niel C, Villela-Nogueira CA, Araujo NM. Genetic variability of hepatitis B and C viruses in Brazilian patients with and without hepatocellular carcinoma. J Med Virol. 2014;86:217-223. [PMID: 24338810 DOI: 10.1002/jmv.23837] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
162 Li Y, Jiang M, Li M, Chen Y, Wei C, Peng L, Liu X, Liu Z, Tong G, Zhou D, He J. Compound Phyllanthus urinaria L Inhibits HBV-Related HCC through HBx-SHH Pathway Axis Inactivation. Evid Based Complement Alternat Med. 2019;2019:1635837. [PMID: 31019539 DOI: 10.1155/2019/1635837] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
163 Li B, Yan C, Zhu J, Chen X, Fu Q, Zhang H, Tong Z, Liu L, Zheng Y, Zhao P, Jiang W, Fang W. Anti-PD-1/PD-L1 Blockade Immunotherapy Employed in Treating Hepatitis B Virus Infection-Related Advanced Hepatocellular Carcinoma: A Literature Review. Front Immunol 2020;11:1037. [PMID: 32547550 DOI: 10.3389/fimmu.2020.01037] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 7.0] [Reference Citation Analysis]
164 Hernanda PY, Pedroza-Gonzalez A, Sprengers D, Peppelenbosch MP, Pan Q. Multipotent mesenchymal stromal cells in liver cancer: implications for tumor biology and therapy. Biochim Biophys Acta 2014;1846:439-45. [PMID: 25204853 DOI: 10.1016/j.bbcan.2014.08.008] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
165 Zhao XL, Yang JR, Lin SZ, Ma H, Guo F, Yang RF, Zhang HH, Han JC, Wei L, Pan XB. Serum viral duplex-linear DNA proportion increases with the progression of liver disease in patients infected with HBV. Gut 2016;65:502-11. [PMID: 26045139 DOI: 10.1136/gutjnl-2014-308989] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 3.5] [Reference Citation Analysis]
166 Zhou L, Wen J, Huang Z, Nice EC, Huang C, Zhang H, Li Q. Redox proteomics screening cellular factors associated with oxidative stress in hepatocarcinogenesis. Proteomics Clin Appl 2017;11. [PMID: 27763721 DOI: 10.1002/prca.201600089] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.6] [Reference Citation Analysis]
167 Bisteau X, Caldez MJ, Kaldis P. The Complex Relationship between Liver Cancer and the Cell Cycle: A Story of Multiple Regulations. Cancers (Basel) 2014;6:79-111. [PMID: 24419005 DOI: 10.3390/cancers6010079] [Cited by in Crossref: 44] [Cited by in F6Publishing: 35] [Article Influence: 6.3] [Reference Citation Analysis]
168 Jalal PJ, King BJ, Saeed A, Adedeji Y, Mason CP, Ball JK, Irving WL, McClure CP, Tarr AW. Elevated serum activity of MBL and ficolin-2 as biomarkers for progression to hepatocellular carcinoma in chronic HCV infection. Virology 2019;530:99-106. [PMID: 30798068 DOI: 10.1016/j.virol.2019.02.002] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
169 Guo JC, Yang YJ, Zheng JF, Zhang JQ, Guo M, Yang X, Jiang XL, Xiang L, Li Y, Ping H, Zhuo L. Silencing of long noncoding RNA HOXA11-AS inhibits the Wnt signaling pathway via the upregulation of HOXA11 and thereby inhibits the proliferation, invasion, and self-renewal of hepatocellular carcinoma stem cells. Exp Mol Med 2019;51:1-20. [PMID: 31757938 DOI: 10.1038/s12276-019-0328-x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
170 Tsai IT, Wang CP, Yu TH, Lu YC, Lin CW, Lu LF, Wu CC, Chung FM, Lee YJ, Hung WC, Hsu CC. Circulating visfatin level is associated with hepatocellular carcinoma in chronic hepatitis B or C virus infection. Cytokine. 2017;90:54-59. [PMID: 27770715 DOI: 10.1016/j.cyto.2016.10.007] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
171 O'Brien TR, Jackson SS. What Have We Learned from Studies of IFN-λ Variants and Hepatitis C Virus Infection? J Interferon Cytokine Res 2019;39:618-26. [PMID: 31161939 DOI: 10.1089/jir.2019.0048] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
172 Randhawa S. CRISPR-Cas9 in cancer therapeutics. Prog Mol Biol Transl Sci 2021;181:129-63. [PMID: 34127191 DOI: 10.1016/bs.pmbts.2021.01.016] [Reference Citation Analysis]
173 Strasser SI. Managing hepatitis B to prevent liver cancer: recent advances. Expert Rev Gastroenterol Hepatol 2014;8:409-15. [PMID: 24580046 DOI: 10.1586/17474124.2014.893823] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
174 Tsuda T, Kaibori M, Hishikawa H, Nakatake R, Okumura T, Ozeki E, Hara I, Morimoto Y, Yoshii K, Kon M. Near-infrared fluorescence imaging and photodynamic therapy with indocyanine green lactosome has antineoplastic effects for hepatocellular carcinoma. PLoS One 2017;12:e0183527. [PMID: 28859104 DOI: 10.1371/journal.pone.0183527] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 3.5] [Reference Citation Analysis]
175 Wan J, Liu S, Sun W, Yu H, Tang W, Liu W, Ji J, Liu B. Ring finger protein 152-dependent degradation of TSPAN12 suppresses hepatocellular carcinoma progression.Cancer Cell Int. 2021;21:122. [PMID: 33602225 DOI: 10.1186/s12935-021-01806-1] [Reference Citation Analysis]
176 Amaddeo G, Cao Q, Ladeiro Y, Imbeaud S, Nault JC, Jaoui D, Gaston Mathe Y, Laurent C, Laurent A, Bioulac-Sage P, Calderaro J, Zucman-Rossi J. Integration of tumour and viral genomic characterizations in HBV-related hepatocellular carcinomas. Gut. 2015;64:820-829. [PMID: 25021421 DOI: 10.1136/gutjnl-2013-306228] [Cited by in Crossref: 86] [Cited by in F6Publishing: 73] [Article Influence: 12.3] [Reference Citation Analysis]
177 Ding B, Bao C, Jin L, Xu L, Fan W, Lou W. CASK Silence Overcomes Sorafenib Resistance of Hepatocellular Carcinoma Through Activating Apoptosis and Autophagic Cell Death. Front Oncol 2021;11:681683. [PMID: 34249726 DOI: 10.3389/fonc.2021.681683] [Reference Citation Analysis]
178 Lévy P, Bartosch B. Metabolic reprogramming: a hallmark of viral oncogenesis. Oncogene 2016;35:4155-64. [DOI: 10.1038/onc.2015.479] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 3.8] [Reference Citation Analysis]
179 Li L, Huang K, Zhao H, Chen B, Ye Q, Yue J. CDK1-PLK1/SGOL2/ANLN pathway mediating abnormal cell division in cell cycle may be a critical process in hepatocellular carcinoma. Cell Cycle 2020;19:1236-52. [PMID: 32275843 DOI: 10.1080/15384101.2020.1749471] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
180 Gade TP, Hunt SJ, Harrison N, Nadolski GJ, Weber C, Pickup S, Furth EE, Schnall MD, Soulen MC, Celeste Simon M. Segmental Transarterial Embolization in a Translational Rat Model of Hepatocellular Carcinoma. J Vasc Interv Radiol. 2015;26:1229-1237. [PMID: 25863596 DOI: 10.1016/j.jvir.2015.02.006] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 3.3] [Reference Citation Analysis]
181 Sinigaglia A, Lavezzo E, Trevisan M, Sanavia T, Di Camillo B, Peta E, Scarpa M, Castagliuolo I, Guido M, Sarcognato S, Cappellesso R, Fassina A, Cardin R, Farinati F, Palù G, Barzon L. Changes in microRNA expression during disease progression in patients with chronic viral hepatitis. Liver Int 2015;35:1324-33. [PMID: 25417901 DOI: 10.1111/liv.12737] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
182 Wettengel JM, Burwitz BJ. Innovative HBV Animal Models Based on the Entry Receptor NTCP. Viruses 2020;12:E828. [PMID: 32751581 DOI: 10.3390/v12080828] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
183 Huang JL, Ren TY, Cao SW, Zheng SH, Hu XM, Hu YW, Lin L, Chen J, Zheng L, Wang Q. HBx-related long non-coding RNA DBH-AS1 promotes cell proliferation and survival by activating MAPK signaling in hepatocellular carcinoma. Oncotarget 2015;6:33791-804. [PMID: 26393879 DOI: 10.18632/oncotarget.5667] [Cited by in Crossref: 55] [Cited by in F6Publishing: 53] [Article Influence: 11.0] [Reference Citation Analysis]
184 Chaiwiang N, Poyomtip T. The associations between Toll-like receptor 4 gene polymorphisms and hepatitis C virus infection: a systematic review and meta-analysis. Biosci Rep 2019;39:BSR20182470. [PMID: 30765614 DOI: 10.1042/BSR20182470] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
185 Bak Y, Shin HJ, Bak Is, Yoon DY, Yu DY. Hepatitis B virus X promotes hepatocellular carcinoma development via nuclear protein 1 pathway. Biochem Biophys Res Commun 2015;466:676-81. [PMID: 26392315 DOI: 10.1016/j.bbrc.2015.09.082] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
186 Chen MY, Li ZP, Sun ZN, Ma M. USP9X promotes the progression of hepatocellular carcinoma by regulating beta-catenin. Ir J Med Sci 2020;189:865-71. [PMID: 32065347 DOI: 10.1007/s11845-020-02199-2] [Reference Citation Analysis]
187 Li ZL, Yu JJ, Guo JW, Sui CJ, Dai BH, Zhang WG, Chen TH, Li C, Gu WM, Zhou YH, Wang H, Zhang YM, Mao XH, Pawlik TM, Wang MD, Liang L, Wu H, Lau WY, Wu MC, Shen F, Yang T. Liver resection is justified for multinodular hepatocellular carcinoma in selected patients with cirrhosis: A multicenter analysis of 1,066 patients. Eur J Surg Oncol 2019;45:800-7. [PMID: 30594407 DOI: 10.1016/j.ejso.2018.12.016] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
188 Casper C, Crane H, Menon M, Money D. HIV/AIDS Comorbidities: Impact on Cancer, Noncommunicable Diseases, and Reproductive Health. In: Holmes KK, Bertozzi S, Bloom BR, Jha P, editors. Disease Control Priorities, Third Edition (Volume 6): Major Infectious Diseases. The World Bank; 2017. pp. 45-66. [DOI: 10.1596/978-1-4648-0524-0_ch3] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 2.3] [Reference Citation Analysis]
189 Yan H, Li Z, Shen Q, Wang Q, Tian J, Jiang Q, Gao L. Aberrant expression of cell cycle and material metabolism related genes contributes to hepatocellular carcinoma occurrence. Pathol Res Pract 2017;213:316-21. [PMID: 28238542 DOI: 10.1016/j.prp.2017.01.019] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 7.3] [Reference Citation Analysis]
190 Mesri EA, Feitelson MA, Munger K. Human viral oncogenesis: a cancer hallmarks analysis. Cell Host Microbe 2014;15:266-82. [PMID: 24629334 DOI: 10.1016/j.chom.2014.02.011] [Cited by in Crossref: 310] [Cited by in F6Publishing: 262] [Article Influence: 44.3] [Reference Citation Analysis]
191 Zhu H, Wu J, Shen X. Genome-wide association study: new genetic insights into HBV/HCV-related hepatocellular carcinoma genomes. Scand J Gastroenterol. 2017;52:209-215. [PMID: 27797287 DOI: 10.1080/00365521.2016.1245778] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
192 Guerrieri F, Belloni L, Pediconi N, Levrero M. Pathobiology of Hepatitis B Virus-Induced Carcinogenesis. In: Liaw Y, Zoulim F, editors. Hepatitis B Virus in Human Diseases. Cham: Springer International Publishing; 2016. pp. 95-121. [DOI: 10.1007/978-3-319-22330-8_5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
193 Sukowati CH, El-Khobar KE, Ie SI, Anfuso B, Muljono DH, Tiribelli C. Significance of hepatitis virus infection in the oncogenic initiation of hepatocellular carcinoma. World J Gastroenterol. 2016;22:1497-1512. [PMID: 26819517 DOI: 10.3748/wjg.v22.i4.1497] [Cited by in CrossRef: 32] [Cited by in F6Publishing: 29] [Article Influence: 8.0] [Reference Citation Analysis]
194 Wittmann P, Grubinger M, Gröger C, Huber H, Sieghart W, Peck-Radosavljevic M, Mikulits W. Neuropilin-2 induced by transforming growth factor-β augments migration of hepatocellular carcinoma cells. BMC Cancer 2015;15:909. [PMID: 26573807 DOI: 10.1186/s12885-015-1919-0] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
195 Hesketh RL, Zhu AX, Oklu R. Hepatocellular carcinoma: can circulating tumor cells and radiogenomics deliver personalized care? Am J Clin Oncol 2015;38:431-6. [PMID: 25238287 DOI: 10.1097/COC.0000000000000123] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
196 Liu J, Tang W, Budhu A, Forgues M, Hernandez MO, Candia J, Kim Y, Bowman ED, Ambs S, Zhao Y, Tran B, Wu X, Koh C, Surana P, Liang TJ, Guarnera M, Mann D, Rajaure M, Greten TF, Wang Z, Yu H, Wang XW. A Viral Exposure Signature Defines Early Onset of Hepatocellular Carcinoma.Cell. 2020;182:317-328.e10. [PMID: 32526205 DOI: 10.1016/j.cell.2020.05.038] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 12.0] [Reference Citation Analysis]
197 Weng Y, Sui Z, Shan Y, Jiang H, Zhou Y, Zhu X, Liang Z, Zhang L, Zhang Y. In-Depth Proteomic Quantification of Cell Secretome in Serum-Containing Conditioned Medium. Anal Chem 2016;88:4971-8. [DOI: 10.1021/acs.analchem.6b00910] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 5.0] [Reference Citation Analysis]
198 Cheng X, Zhong F, He K, Sun S, Chen H, Zhou J. EHHM, a novel phenolic natural product from Livistona chinensis, induces autophagy-related apoptosis in hepatocellular carcinoma cells. Oncol Lett 2016;12:3739-48. [PMID: 27895725 DOI: 10.3892/ol.2016.5178] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
199 Jeng KS, Sheen IS, Leu CM, Tseng PH, Chang CF. The Role of Smoothened in Cancer. Int J Mol Sci 2020;21:E6863. [PMID: 32962123 DOI: 10.3390/ijms21186863] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
200 Li YL, Zhang NY, Hu X, Chen JL, Rao MJ, Wu LW, Li QY, Zhang B, Yan W, Zhang C. Evodiamine induces apoptosis and promotes hepatocellular carcinoma cell death induced by vorinostat via downregulating HIF-1α under hypoxia. Biochem Biophys Res Commun 2018;498:481-6. [PMID: 29505792 DOI: 10.1016/j.bbrc.2018.03.004] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 4.7] [Reference Citation Analysis]
201 Ye H, Zhang C, Wang BJ, Tan XH, Zhang WP, Teng Y, Yang X. Synergistic function of Kras mutation and HBx in initiation and progression of hepatocellular carcinoma in mice. Oncogene. 2014;33:5133-5138. [PMID: 24213574 DOI: 10.1038/onc.2013.468] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 3.8] [Reference Citation Analysis]
202 Tian Z. Outflanking HCV. Nat Immunol 2014;15:6-8. [PMID: 24352316 DOI: 10.1038/ni.2783] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
203 Ma X, Meng Z, Jin L, Xiao Z, Wang X, Tsark WM, Ding L, Gu Y, Zhang J, Kim B, He M, Gan X, Shively JE, Yu H, Xu R, Huang W. CAMK2γ in intestinal epithelial cells modulates colitis-associated colorectal carcinogenesis via enhancing STAT3 activation. Oncogene 2017;36:4060-71. [PMID: 28319059 DOI: 10.1038/onc.2017.16] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 4.3] [Reference Citation Analysis]
204 Abdelrheem DA, Abd El-Mageed HR, Mohamed HS, Rahman AA, Elsayed KNM, Ahmed SA. Bis-indole alkaloid caulerpin from a new source Sargassum platycarpum: isolation, characterization, in vitro anticancer activity, binding with nucleobases by DFT calculations and MD simulation. J Biomol Struct Dyn 2021;39:5137-47. [PMID: 32579063 DOI: 10.1080/07391102.2020.1784285] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
205 Liu Y, Yang Y, Wang T, Wang L, Wang X, Li T, Shi Y, Wang Y. Long non-coding RNA CCAL promotes hepatocellular carcinoma progression by regulating AP-2α and Wnt/β-catenin pathway. Int J Biol Macromol 2018;109:424-34. [PMID: 29275200 DOI: 10.1016/j.ijbiomac.2017.12.110] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 4.3] [Reference Citation Analysis]
206 Cui H, Gao Q, Zhang L, Han F, Wang L. Knockdown of FOXK1 suppresses liver cancer cell viability by inhibiting glycolysis. Life Sciences 2018;213:66-73. [DOI: 10.1016/j.lfs.2018.10.018] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
207 Naito Y, Tanaka Y, Ochiya T. microRNAs and Hepatitis B. Adv Exp Med Biol 2015;888:389-99. [PMID: 26663193 DOI: 10.1007/978-3-319-22671-2_19] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
208 Thillai K, Ross P, Sarker D. Molecularly targeted therapy for advanced hepatocellular carcinoma - a drug development crisis? World J Gastrointest Oncol. 2016;8:173-185. [PMID: 26909132 DOI: 10.4251/wjgo.v8.i2.173] [Cited by in CrossRef: 25] [Cited by in F6Publishing: 19] [Article Influence: 5.0] [Reference Citation Analysis]
209 Li XY, Bai MJ, Chen LJ, Xu JL, Lin ZH, Li X, Xing YF. Issue in statistical strategy in case-control study. Hepatology 2015;62:320. [PMID: 25477185 DOI: 10.1002/hep.27633] [Reference Citation Analysis]
210 Pezzuto F, Buonaguro L, Buonaguro FM, Tornesello ML. Frequency and geographic distribution of TERT promoter mutations in primary hepatocellular carcinoma. Infect Agent Cancer. 2017;12:27. [PMID: 28529542 DOI: 10.1186/s13027-017-0138-5] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
211 Tzanakakis G, Neagu M, Tsatsakis A, Nikitovic D. Proteoglycans and Immunobiology of Cancer-Therapeutic Implications. Front Immunol 2019;10:875. [PMID: 31068944 DOI: 10.3389/fimmu.2019.00875] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 9.0] [Reference Citation Analysis]
212 Ueda T, Honda M, Horimoto K, Aburatani S, Saito S, Yamashita T, Sakai Y, Nakamura M, Takatori H, Sunagozaka H. Gene expression profiling of hepatitis B- and hepatitis C-related hepatocellular carcinoma using graphical Gaussian modeling. Genomics. 2013;101:238-248. [PMID: 23485556 DOI: 10.1016/j.ygeno.2013.02.007] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
213 Chen R, Hou W, Zhang Q, Kang R, Fan XG, Tang D. Emerging role of high-mobility group box 1 (HMGB1) in liver diseases. Mol Med. 2013;19:357-366. [PMID: 24306421 DOI: 10.2119/molmed.2013.00099] [Cited by in Crossref: 50] [Cited by in F6Publishing: 60] [Article Influence: 6.3] [Reference Citation Analysis]
214 Yen CJ, Yang ST, Chen RY, Huang W, Chayama K, Lee MH, Yang SJ, Lai HS, Yen HY, Hsiao YW, Wang JM, Lin YJ, Hung LY. Hepatitis B virus X protein (HBx) enhances centrosomal P4.1-associated protein (CPAP) expression to promote hepatocarcinogenesis. J Biomed Sci 2019;26:44. [PMID: 31170980 DOI: 10.1186/s12929-019-0534-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
215 Liu D, Qian T, Sun S, Jiang JJ. Laryngopharyngeal Reflux and Inflammatory Responses in Mucosal Barrier Dysfunction of the Upper Aerodigestive Tract. J Inflamm Res 2020;13:1291-304. [PMID: 33447069 DOI: 10.2147/JIR.S282809] [Reference Citation Analysis]
216 Uchida D, Takaki A, Oyama A, Adachi T, Wada N, Onishi H, Okada H. Oxidative Stress Management in Chronic Liver Diseases and Hepatocellular Carcinoma. Nutrients 2020;12:E1576. [PMID: 32481552 DOI: 10.3390/nu12061576] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 11.0] [Reference Citation Analysis]
217 You N, Li J, Huang X, Wu K, Tang Y, Wang L, Li H, Mi N, Zheng L. COMMD7 promotes hepatocellular carcinoma through regulating CXCL10. Biomed Pharmacother 2017;88:653-7. [PMID: 28142122 DOI: 10.1016/j.biopha.2017.01.046] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
218 Pan XY, Huang C, Li J. The emerging roles of m6A modification in liver carcinogenesis. Int J Biol Sci 2021;17:271-84. [PMID: 33390849 DOI: 10.7150/ijbs.50003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
219 Yazdani HO, Huang H, Tsung A. Autophagy: Dual Response in the Development of Hepatocellular Carcinoma. Cells. 2019;8. [PMID: 30695997 DOI: 10.3390/cells8020091] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 14.0] [Reference Citation Analysis]
220 Zhang W, Zhangyuan G, Wang F, Jin K, Shen H, Zhang L, Yuan X, Wang J, Zhang H, Yu W, Huang R, Xu X, Yin Y, Zhong G, Lin A, Sun B. The zinc finger protein Miz1 suppresses liver tumorigenesis by restricting hepatocyte-driven macrophage activation and inflammation. Immunity 2021;54:1168-1185.e8. [PMID: 34038747 DOI: 10.1016/j.immuni.2021.04.027] [Reference Citation Analysis]
221 Wang ZG, Zheng H, Gao W, Han J, Cao JZ, Yang Y, Li S, Gao R, Liu H, Pan ZY, Fu SY, Gu FM, Xing H, Ni JS, Yan HL, Ren H, Zhou WP. eIF5B increases ASAP1 expression to promote HCC proliferation and invasion. Oncotarget 2016;7:62327-39. [PMID: 27694689 DOI: 10.18632/oncotarget.11469] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
222 Bility MT, Cheng L, Zhang Z, Luan Y, Li F, Chi L, Zhang L, Tu Z, Gao Y, Fu Y, Niu J, Wang F, Su L. Hepatitis B virus infection and immunopathogenesis in a humanized mouse model: Induction of human-specific liver fibrosis and M2-like macrophages. PLoS Pathog. 2014;10:e1004032. [PMID: 24651854 DOI: 10.1371/journal.ppat.1004032] [Cited by in Crossref: 127] [Cited by in F6Publishing: 131] [Article Influence: 18.1] [Reference Citation Analysis]
223 Li W, Wu H, Xu X, Zhang Y. Comprehensive analysis of genomic and immunological profiles in Chinese and Western hepatocellular carcinoma populations. Aging (Albany NY) 2021;13:11564-94. [PMID: 33867349 DOI: 10.18632/aging.202853] [Reference Citation Analysis]
224 Shen H, Zheng S, Chen R, Jin X, Xu X, Jing C, Lin J, Zhang J, Zhang M, Zhang L, Xie X, Guo K, Ren Z, Lin S, Zhang B. Prognostic significance of serum procalcitonin in patients with unresectable hepatocellular carcinoma treated with transcatheter arterial chemoembolization: A retrospective analysis of 509 cases. Medicine (Baltimore) 2017;96:e7438. [PMID: 28700480 DOI: 10.1097/MD.0000000000007438] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
225 Ratnoglik SL, Aoki C, Sudarmono P, Komoto M, Deng L, Shoji I, Fuchino H, Kawahara N, Hotta H. Antiviral activity of extracts from Morinda citrifolia leaves and chlorophyll catabolites, pheophorbide a and pyropheophorbide a, against hepatitis C virus: Anti-HCV activity of pheophorbide a. Microbiol Immunol 2014;58:188-94. [DOI: 10.1111/1348-0421.12133] [Cited by in Crossref: 34] [Cited by in F6Publishing: 19] [Article Influence: 4.9] [Reference Citation Analysis]
226 Duan J, Wu Y, Liu J, Zhang J, Fu Z, Feng T, Liu M, Han J, Li Z, Chen S. Genetic Biomarkers For Hepatocellular Carcinoma In The Era Of Precision Medicine.J Hepatocell Carcinoma. 2019;6:151-166. [PMID: 31696097 DOI: 10.2147/JHC.S224849] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 4.5] [Reference Citation Analysis]
227 Khlaiphuengsin A, Chuaypen N, Sodsai P, Buranapraditkun S, Boonpiyathad T, Hirankarn N, Tangkijvanich P. Decreased of BAFF-R expression and B cells maturation in patients with hepatitis B virus-related hepatocellular carcinoma. World J Gastroenterol 2020;26:2645-56. [PMID: 32523317 DOI: 10.3748/wjg.v26.i20.2645] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
228 Wang X, Zhang M, Ping F, Liu H, Sun J, Wang Y, Shen A, Ding J, Geng M. Identification and Therapeutic Intervention of Coactivated Anaplastic Lymphoma Kinase, Fibroblast Growth Factor Receptor 2, and Ephrin Type-A Receptor 5 Kinases in Hepatocellular Carcinoma. Hepatology 2019;69:573-86. [PMID: 29356025 DOI: 10.1002/hep.29792] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
229 Wu SY, Lan SH, Wu SR, Chiu YC, Lin XZ, Su IJ, Tsai TF, Yen CJ, Lu TH, Liang FW, Li CY, Su HJ, Su CL, Liu HS. Hepatocellular carcinoma-related cyclin D1 is selectively regulated by autophagy degradation system. Hepatology 2018;68:141-54. [PMID: 29328502 DOI: 10.1002/hep.29781] [Cited by in Crossref: 40] [Cited by in F6Publishing: 37] [Article Influence: 13.3] [Reference Citation Analysis]
230 Lan QY, Liao GC, Zhou RF, Chen PY, Wang XY, Chen MS, Chen YM, Zhu HL. Dietary patterns and primary liver cancer in Chinese adults: a case-control study. Oncotarget 2018;9:27872-81. [PMID: 29963244 DOI: 10.18632/oncotarget.23910] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
231 Martin M, Ancey PB, Cros MP, Durand G, Le Calvez-Kelm F, Hernandez-Vargas H, Herceg Z. Dynamic imbalance between cancer cell subpopulations induced by transforming growth factor beta (TGF-β) is associated with a DNA methylome switch. BMC Genomics. 2014;15:435. [PMID: 24898317 DOI: 10.1186/1471-2164-15-435] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 2.7] [Reference Citation Analysis]
232 Kaibori M, Yoshii K, Hasegawa K, Ogawa A, Kubo S, Tateishi R, Izumi N, Kadoya M, Kudo M, Kumada T, Sakamoto M, Nakashima O, Matsuyama Y, Takayama T, Kokudo N. Treatment Optimization for Hepatocellular Carcinoma in Elderly Patients in a Japanese Nationwide Cohort. Annals of Surgery 2019;270:121-30. [DOI: 10.1097/sla.0000000000002751] [Cited by in Crossref: 20] [Cited by in F6Publishing: 13] [Article Influence: 10.0] [Reference Citation Analysis]
233 White MK, Pagano JS, Khalili K. Viruses and human cancers: a long road of discovery of molecular paradigms. Clin Microbiol Rev. 2014;27:463-481. [PMID: 24982317 DOI: 10.1128/cmr.00124-13] [Cited by in Crossref: 93] [Cited by in F6Publishing: 40] [Article Influence: 15.5] [Reference Citation Analysis]
234 Hu C, Zhu S, Wang J, Lin Y, Ma L, Zhu L, Jiang P, Li Z, Pan W. Schistosoma japonicum MiRNA-7-5p Inhibits the Growth and Migration of Hepatoma Cells via Cross-Species Regulation of S-Phase Kinase-Associated Protein 2. Front Oncol 2019;9:175. [PMID: 30967999 DOI: 10.3389/fonc.2019.00175] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 4.5] [Reference Citation Analysis]
235 Song IJ, Yang YM, Inokuchi-Shimizu S, Roh YS, Yang L, Seki E. The contribution of toll-like receptor signaling to the development of liver fibrosis and cancer in hepatocyte-specific TAK1-deleted mice. Int J Cancer. 2018;142:81-91. [PMID: 28875549 DOI: 10.1002/ijc.31029] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 5.5] [Reference Citation Analysis]
236 Hong X, Kim ES, Guo H. Epigenetic regulation of hepatitis B virus covalently closed circular DNA: Implications for epigenetic therapy against chronic hepatitis B. Hepatology 2017;66:2066-77. [PMID: 28833361 DOI: 10.1002/hep.29479] [Cited by in Crossref: 84] [Cited by in F6Publishing: 78] [Article Influence: 21.0] [Reference Citation Analysis]
237 Wang Z, Wu J, Zhang G, Cao Y, Jiang C, Ding Y. Associations of miR-499 and miR-34b/c Polymorphisms with Susceptibility to Hepatocellular Carcinoma: An Evidence-Based Evaluation. Gastroenterol Res Pract 2013;2013:719202. [PMID: 24194751 DOI: 10.1155/2013/719202] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
238 Li C, Lin C, Cong X, Jiang Y. PDK1-WNK1 signaling is affected by HBx and involved in the viability and metastasis of hepatic cells. Oncol Lett 2018;15:5940-6. [PMID: 29563998 DOI: 10.3892/ol.2018.8001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
239 Shehata F, Abdel Monem N, Sakr M, Kasem S, Balbaa M. Epidermal growth factor, its receptor and transforming growth factor-β1 in the diagnosis of HCV-induced hepatocellular carcinoma. Med Oncol 2013;30:673. [PMID: 23912699 DOI: 10.1007/s12032-013-0673-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
240 Wu L, Yang F, Lin B, Chen X, Yin S, Zhang F, Xie H, Zhou L, Zheng S. MicroRNA-424 expression predicts tumor recurrence in patients with hepatocellular carcinoma following liver transplantation. Oncol Lett 2018;15:9126-32. [PMID: 29805644 DOI: 10.3892/ol.2018.8539] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
241 Marônek M, Link R, Monteleone G, Gardlík R, Stolfi C. Viruses in Cancers of the Digestive System: Active Contributors or Idle Bystanders? Int J Mol Sci 2020;21:E8133. [PMID: 33143318 DOI: 10.3390/ijms21218133] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
242 Chen SR, Qiu HC, Hu Y, Wang Y, Wang YT. Herbal Medicine Offered as an Initiative Therapeutic Option for the Management of Hepatocellular Carcinoma. Phytother Res 2016;30:863-77. [PMID: 26879574 DOI: 10.1002/ptr.5594] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 3.6] [Reference Citation Analysis]
243 Cheng L, Zhang Z, Zuo D, Zhu W, Zhang J, Zeng Q, Yang D, Li M, Zhao Y. Ultrasensitive Detection of Serum MicroRNA Using Branched DNA-Based SERS Platform Combining Simultaneous Detection of α-Fetoprotein for Early Diagnosis of Liver Cancer. ACS Appl Mater Interfaces 2018;10:34869-77. [PMID: 30238748 DOI: 10.1021/acsami.8b10252] [Cited by in Crossref: 28] [Cited by in F6Publishing: 15] [Article Influence: 9.3] [Reference Citation Analysis]
244 Jia HD, Liang L, Li C, Wu H, Wang H, Liang YJ, Zhou YH, Gu WM, Fan XP, Zhang WG, Chen TH, Chen ZY, Zhong JH, Lau WY, Pawlik TM, Diao YK, Xu QR, Shen F, Zhang CW, Huang DS, Yang T. Long-Term Surgical Outcomes of Liver Resection for Hepatocellular Carcinoma in Patients With HBV and HCV Co-Infection: A Multicenter Observational Study. Front Oncol 2021;11:700228. [PMID: 34395268 DOI: 10.3389/fonc.2021.700228] [Reference Citation Analysis]
245 Mosca E, Alfieri R, Milanesi L. Diffusion of information throughout the host interactome reveals gene expression variations in network proximity to target proteins of hepatitis C virus. PLoS One 2014;9:e113660. [PMID: 25461596 DOI: 10.1371/journal.pone.0113660] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
246 Zhai N, Li H, Song H, Yang Y, Cui A, Li T, Niu J, Crispe IN, Su L, Tu Z. Hepatitis C Virus Induces MDSCs-Like Monocytes through TLR2/PI3K/AKT/STAT3 Signaling. PLoS One. 2017;12:e0170516. [PMID: 28114346 DOI: 10.1371/journal.pone.0170516] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 7.3] [Reference Citation Analysis]
247 Fu XH, Li M, Lou HB, Huang MS, Liu CL. Investigating genetic characteristics of hepatitis B virus-associated and -non-associated hepatocellular carcinoma. Genet Res (Camb) 2016;98:e14. [PMID: 27834158 DOI: 10.1017/S0016672316000124] [Reference Citation Analysis]
248 Ferrell LD, Kakar S, Terracciano LM, Wee A. Tumours and Tumour-like Lesions of the Liver. Macsween's Pathology of the Liver. Elsevier; 2018. pp. 780-879. [DOI: 10.1016/b978-0-7020-6697-9.00013-3] [Cited by in Crossref: 5] [Article Influence: 1.7] [Reference Citation Analysis]
249 Peng JL, Wu JZ, Li GJ, Wu JL, Xi YM, Li XQ, Wang L. Association of RASSF1A hypermethylation with risk of HBV/HCV-induced hepatocellular carcinoma: A meta-analysis. Pathol Res Pract 2020;216:153099. [PMID: 32853942 DOI: 10.1016/j.prp.2020.153099] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
250 Han C, Jiang Y, Wang Z, Wang H. Natural killer cells involved in tumour immune escape of hepatocellular carcinomar. Int Immunopharmacol 2019;73:10-6. [PMID: 31078921 DOI: 10.1016/j.intimp.2019.04.057] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
251 Piciocchi M, Cardin R, Cillo U, Vitale A, Cappon A, Mescoli C, Guido M, Rugge M, Burra P, Floreani A, Farinati F. Differential timing of oxidative DNA damage and telomere shortening in hepatitis C and B virus-related liver carcinogenesis. Transl Res 2016;168:122-33. [PMID: 26408804 DOI: 10.1016/j.trsl.2015.08.012] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
252 Nakatake R, Kaibori M, Nakamura Y, Tanaka Y, Matushima H, Okumura T, Murakami T, Ino Y, Todo T, Kon M. Third-generation oncolytic herpes simplex virus inhibits the growth of liver tumors in mice. Cancer Sci 2018;109:600-10. [PMID: 29288515 DOI: 10.1111/cas.13492] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
253 Wang J, Xu L, Zeng W, Hu P, Zeng M, Rabkin SD, Liu R. Treatment of human hepatocellular carcinoma by the oncolytic herpes simplex virus G47delta. Cancer Cell Int 2014;14:83. [PMID: 25360068 DOI: 10.1186/s12935-014-0083-y] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
254 Zhang Q, Chen J, Pan M, Liu J, Liu T, Zhou Y. Comparison of replication competence of wild-type and lamivudine-resistant hepatitis B virus isolates from a chronic hepatitis B patient. Virus Research 2018;255:165-70. [DOI: 10.1016/j.virusres.2018.07.021] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
255 Wang Q, Luan W, Warren L, Kadri H, Kim KW, Goz V, Blank S, Isabel Fiel M, Hiotis SP. Autologous Tumor Cell Lysate-Loaded Dendritic Cell Vaccine Inhibited Tumor Progression in an Orthotopic Murine Model for Hepatocellular Carcinoma. Ann Surg Oncol. 2016;23:574-582. [PMID: 26786094 DOI: 10.1245/s10434-015-5035-9] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
256 Giraldo NA, Becht E, Remark R, Damotte D, Sautès-fridman C, Fridman WH. The immune contexture of primary and metastatic human tumours. Current Opinion in Immunology 2014;27:8-15. [DOI: 10.1016/j.coi.2014.01.001] [Cited by in Crossref: 71] [Cited by in F6Publishing: 67] [Article Influence: 10.1] [Reference Citation Analysis]
257 Yen TT, Yang A, Chiu WT, Li TN, Wang LH, Wu YH, Wang HC, Chen L, Wang WC, Huang W. Hepatitis B virus PreS2-mutant large surface antigen activates store-operated calcium entry and promotes chromosome instability. Oncotarget. 2016;7:23346-23360. [PMID: 26992221 DOI: 10.18632/oncotarget.8109] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 6.3] [Reference Citation Analysis]
258 Shiryaev SA, Remacle AG, Chernov AV, Golubkov VS, Motamedchaboki K, Muranaka N, Dambacher CM, Capek P, Kukreja M, Kozlov IA, Perucho M, Cieplak P, Strongin AY. Substrate cleavage profiling suggests a distinct function of Bacteroides fragilis metalloproteinases (fragilysin and metalloproteinase II) at the microbiome-inflammation-cancer interface. J Biol Chem. 2013;288:34956-34967. [PMID: 24145028 DOI: 10.1074/jbc.m113.516153] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 2.4] [Reference Citation Analysis]
259 Zhong Y, Li Y, Song T, Zhang D. MiR-718 mediates the indirect interaction between lncRNA SEMA3B-AS1 and PTEN to regulate the proliferation of hepatocellular carcinoma cells. Physiol Genomics 2019;51:500-5. [PMID: 31251699 DOI: 10.1152/physiolgenomics.00019.2019] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
260 Yu LX, Ling Y, Wang HY. Role of nonresolving inflammation in hepatocellular carcinoma development and progression. NPJ Precis Oncol 2018;2:6. [PMID: 29872724 DOI: 10.1038/s41698-018-0048-z] [Cited by in Crossref: 75] [Cited by in F6Publishing: 70] [Article Influence: 25.0] [Reference Citation Analysis]
261 Shao LN, Zhou SH, Wang N, Zhang ST, Liu M. Association between the Genetic Polymorphisms of CCL2, CCL5, CCL8, CCR2, and CCR5 with Chronic Hepatitis C Virus Infection in the Chinese Han Population. Immunol Invest 2021;:1-16. [PMID: 33902378 DOI: 10.1080/08820139.2021.1916524] [Reference Citation Analysis]
262 Wang J, Zheng X, Peng Q, Zhang X, Qin Z. Eph receptors: the bridge linking host and virus. Cell Mol Life Sci 2020;77:2355-65. [PMID: 31893311 DOI: 10.1007/s00018-019-03409-6] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 7.0] [Reference Citation Analysis]
263 Wang W, Bai G, Zhang Y, Zhang T, Li C, Yuan Y, Liu S, Wang C. HBxAg suppresses cell apoptosis and promotes the secretion of placental hormones in human placental trophoblasts via activation of the EGFR/Akt pathway. Cell Biol Int 2018;42:237-47. [PMID: 29052908 DOI: 10.1002/cbin.10891] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
264 Pan Y, Wang B, Yang X, Bai F, Xu Q, Li X, Gao L, Ma C, Liang X. CUL4A facilitates hepatocarcinogenesis by promoting cell cycle progression and epithelial-mesenchymal transition. Sci Rep 2015;5:17006. [PMID: 26593394 DOI: 10.1038/srep17006] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 3.2] [Reference Citation Analysis]
265 Selitsky SR, Dinh TA, Toth CL, Kurtz CL, Honda M, Struck BR, Kaneko S, Vickers KC, Lemon SM, Sethupathy P. Transcriptomic Analysis of Chronic Hepatitis B and C and Liver Cancer Reveals MicroRNA-Mediated Control of Cholesterol Synthesis Programs. mBio 2015;6:e01500-15. [PMID: 26646011 DOI: 10.1128/mBio.01500-15] [Cited by in Crossref: 26] [Cited by in F6Publishing: 15] [Article Influence: 4.3] [Reference Citation Analysis]
266 Zhang C, Wang P, Li Y, Huang C, Ni W, Chen Y, Shi J, Chen G, Hu X, Ye M, Duan S, Wang K. Role of MicroRNAs in the Development of Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease. Anat Rec (Hoboken) 2019;302:193-200. [PMID: 30312023 DOI: 10.1002/ar.23954] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
267 Song MA, Kwee SA, Tiirikainen M, Hernandez BY, Okimoto G, Tsai NC, Wong LL, Yu H. Comparison of genome-scale DNA methylation profiles in hepatocellular carcinoma by viral status. Epigenetics. 2016;11:464-474. [PMID: 27248055 DOI: 10.1080/15592294.2016.1151586] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
268 Ganesan M, Poluektova LY, Kharbanda KK, Osna NA. Human immunodeficiency virus and hepatotropic viruses co-morbidities as the inducers of liver injury progression. World J Gastroenterol 2019;25:398-410. [PMID: 30700937 DOI: 10.3748/wjg.v25.i4.398] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 9] [Article Influence: 7.0] [Reference Citation Analysis]
269 Wang XF, Huang MZ, Zhang XW, Hua RX, Guo WJ. COX-2-765G>C polymorphism increases the risk of cancer: a meta-analysis. PLoS One 2013;8:e73213. [PMID: 24023834 DOI: 10.1371/journal.pone.0073213] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
270 O'Brien TR, Yang HI, Groover S, Jeng WJ. Genetic Factors That Affect Spontaneous Clearance of Hepatitis C or B Virus, Response to Treatment, and Disease Progression. Gastroenterology 2019;156:400-17. [PMID: 30287169 DOI: 10.1053/j.gastro.2018.09.052] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 6.3] [Reference Citation Analysis]
271 Wang D, Li X, Li J, Lu Y, Zhao S, Tang X, Chen X, Li J, Zheng Y, Li S, Sun R, Yan M, Yu D, Cao G, Yang Y. APOBEC3B interaction with PRC2 modulates microenvironment to promote HCC progression. Gut 2019;68:1846-57. [PMID: 31154396 DOI: 10.1136/gutjnl-2018-317601] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 8.0] [Reference Citation Analysis]
272 Takaki A, Yamamoto K. Control of oxidative stress in hepatocellular carcinoma: Helpful or harmful? World J Hepatol 2015;7:968-79. [PMID: 25954479 DOI: 10.4254/wjh.v7.i7.968] [Cited by in Crossref: 57] [Cited by in F6Publishing: 51] [Article Influence: 9.5] [Reference Citation Analysis]
273 Xu L, Hazard FK, Zmoos AF, Jahchan N, Chaib H, Garfin PM, Rangaswami A, Snyder MP, Sage J. Genomic analysis of fibrolamellar hepatocellular carcinoma. Hum Mol Genet 2015;24:50-63. [PMID: 25122662 DOI: 10.1093/hmg/ddu418] [Cited by in Crossref: 50] [Cited by in F6Publishing: 44] [Article Influence: 7.1] [Reference Citation Analysis]
274 Lambert MP, Ancey PB, Esposti DD, Cros MP, Sklias A, Scoazec JY, Durantel D, Hernandez-Vargas H, Herceg Z. Aberrant DNA methylation of imprinted loci in hepatocellular carcinoma and after in vitro exposure to common risk factors. Clin Epigenetics 2015;7:15. [PMID: 25755686 DOI: 10.1186/s13148-015-0053-9] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
275 Jeng KS, Jeng CJ, Jeng WJ, Sheen IS, Li SY, Leu CM, Tsay YG, Chang CF. Sonic Hedgehog signaling pathway as a potential target to inhibit the progression of hepatocellular carcinoma. Oncol Lett 2019;18:4377-84. [PMID: 31611946 DOI: 10.3892/ol.2019.10826] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
276 Tang B, Wang J, Hutchison JA, Ma L, Zhang N, Guo H, Hu Z, Li M, Zhao Y. Ultrasensitive, Multiplex Raman Frequency Shift Immunoassay of Liver Cancer Biomarkers in Physiological Media. ACS Nano 2016;10:871-9. [PMID: 26731464 DOI: 10.1021/acsnano.5b06007] [Cited by in Crossref: 72] [Cited by in F6Publishing: 51] [Article Influence: 14.4] [Reference Citation Analysis]
277 Lu L, Jiang Z, Dai Y, Chen L. Low-Grade Dysplastic Nodules Revealed as the Tipping Point during Multistep Hepatocarcinogenesis by Dynamic Network Biomarkers. Genes (Basel). 2017;8. [PMID: 29027943 DOI: 10.3390/genes8100268] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
278 Shi S, Rao Q, Zhang C, Zhang X, Qin Y, Niu Z. Dendritic Cells Pulsed with Exosomes in Combination with PD-1 Antibody Increase the Efficacy of Sorafenib in Hepatocellular Carcinoma Model. Transl Oncol 2018;11:250-8. [PMID: 29413757 DOI: 10.1016/j.tranon.2018.01.001] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 9.3] [Reference Citation Analysis]
279 Gao Y, Fan X, Li N, Du C, Yang B, Qin W, Fu J, Markowitz GJ, Wang H, Ma J, Cheng S, Yang P. CCL22 signaling contributes to sorafenib resistance in hepatitis B virus-associated hepatocellular carcinoma. Pharmacol Res 2020;157:104800. [PMID: 32278046 DOI: 10.1016/j.phrs.2020.104800] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
280 Zhu S, Cao S, Yang W, Che J, Li D, Pei R, Ding Y. The Maturation of Tumor Suppressor miR-497 in Hepatocellular Carcinoma is Inhibited by Oncogenic circRNA SCARB1. Cancer Manag Res 2021;13:5751-9. [PMID: 34305409 DOI: 10.2147/CMAR.S304125] [Reference Citation Analysis]
281 Amougou-Atsama M, Jean Adrien Atangana P, Noah Noah D, Fewou Moundipa P, Pineau P, Njouom R. The role of hepatitis C virus genotypes and core mutations in hepatocellular carcinoma in Cameroon. J Viral Hepat 2020;27:880-5. [PMID: 32301239 DOI: 10.1111/jvh.13303] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
282 Gallo A, Miele M, Badami E, Conaldi PG. Molecular and cellular interplay in virus-induced tumors in solid organ recipients. Cellular Immunology 2019;343:103770. [DOI: 10.1016/j.cellimm.2018.02.010] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
283 Camini FC, da Silva Caetano CC, Almeida LT, de Brito Magalhães CL. Implications of oxidative stress on viral pathogenesis. Arch Virol 2017;162:907-17. [PMID: 28039563 DOI: 10.1007/s00705-016-3187-y] [Cited by in Crossref: 73] [Cited by in F6Publishing: 47] [Article Influence: 14.6] [Reference Citation Analysis]
284 Hamada T, Nowak JA, Milner DA jr. Song M, Ogino S. Integration of microbiology, molecular pathology, and epidemiology: a new paradigm to explore the pathogenesis of microbiome-driven neoplasms. J Pathol. 2019;247:615-628. [PMID: 30632609 DOI: 10.1002/path.5236] [Cited by in Crossref: 48] [Cited by in F6Publishing: 42] [Article Influence: 24.0] [Reference Citation Analysis]
285 Huang Z, Su B, Liu F, Zhang N, Ye Y, Zhang Y, Zhen Z, Liang S, Liang S, Chen L, Luo W, Claret FX, Huang Y, Xu T. YAP1 Promotes Tumor Invasion and Metastasis in Nasopharyngeal Carcinoma with Hepatitis B Virus Infection. Onco Targets Ther 2020;13:5629-42. [PMID: 32606777 DOI: 10.2147/OTT.S247699] [Reference Citation Analysis]
286 Zheng Y, Tang L, Chen G, Liu Z. Comprehensive Bioinformatics Analysis of Key Methyltransferases and Demethylases for Histone Lysines in Hepatocellular Carcinoma. Technol Cancer Res Treat 2020;19:1533033820983284. [PMID: 33355042 DOI: 10.1177/1533033820983284] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
287 Koga H, Kai K, Aishima S, Kawaguchi A, Yamaji K, Ide T, Ueda J, Noshiro H. Occult hepatitis B virus infection and surgical outcomes in non-B, non-C patients with curative resection for hepatocellular carcinoma. World J Hepatol 2017;9:1286-95. [PMID: 29290910 DOI: 10.4254/wjh.v9.i35.1286] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
288 Zhang B, Liu Y, Wang X, Li J, Xu X, Guo L, Ho WZ. TLR3 Activation of Hepatic Stellate Cell Line Suppresses HBV Replication in HepG2 Cells. Front Immunol 2018;9:2921. [PMID: 30619284 DOI: 10.3389/fimmu.2018.02921] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
289 Becht E, Giraldo NA, Germain C, de Reyniès A, Laurent-puig P, Zucman-rossi J, Dieu-nosjean M, Sautès-fridman C, Fridman WH. Immune Contexture, Immunoscore, and Malignant Cell Molecular Subgroups for Prognostic and Theranostic Classifications of Cancers. Tumor Immunology. Elsevier; 2016. pp. 95-190. [DOI: 10.1016/bs.ai.2015.12.002] [Cited by in Crossref: 102] [Cited by in F6Publishing: 94] [Article Influence: 20.4] [Reference Citation Analysis]
290 Amougou MA, Noah DN, Moundipa PF, Pineau P, Njouom R. A prominent role of Hepatitis D Virus in liver cancers documented in Central Africa. BMC Infect Dis 2016;16:647. [PMID: 27821080 DOI: 10.1186/s12879-016-1992-2] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 4.6] [Reference Citation Analysis]
291 Sun Y, Ma W, Yang Y, He M, Li A, Bai L, Yu B, Yu Z. Cancer nanotechnology: Enhancing tumor cell response to chemotherapy for hepatocellular carcinoma therapy. Asian J Pharm Sci 2019;14:581-94. [PMID: 32104485 DOI: 10.1016/j.ajps.2019.04.005] [Cited by in Crossref: 65] [Cited by in F6Publishing: 39] [Article Influence: 32.5] [Reference Citation Analysis]
292 Lim HC, Gordan JD. Tumor hepatitis B virus RNA identifies a clinically and molecularly distinct subset of hepatocellular carcinoma. PLoS Comput Biol 2021;17:e1008699. [PMID: 33561166 DOI: 10.1371/journal.pcbi.1008699] [Reference Citation Analysis]
293 Lin C, Huang X, Liu H, Wang Y. Interactions of Hepatitis B Virus Infection with Nonalcoholic Fatty Liver Disease: Possible Mechanisms and Clinical Impact. Dig Dis Sci 2015;60:3513-24. [DOI: 10.1007/s10620-015-3772-z] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 4.5] [Reference Citation Analysis]
294 Turkes F, Mencel J, Starling N. Targeting the immune milieu in gastrointestinal cancers. J Gastroenterol 2020;55:909-26. [PMID: 32748171 DOI: 10.1007/s00535-020-01710-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
295 Wang Q, Luan W, Warren L, Fiel MI, Blank S, Kadri H, Tuvin D, Hiotis SP. Serum hepatitis B surface antigen correlates with tissue covalently closed circular DNA in patients with hepatitis B-associated hepatocellular carcinoma: HBsAg in HBV-HCC. J Med Virol 2016;88:244-51. [DOI: 10.1002/jmv.24326] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
296 Zhou H, Cai Y, Liu D, Li M, Sha Y, Zhang W, Wang K, Gong J, Tang N, Huang A, Xia J. Pharmacological or transcriptional inhibition of both HDAC1 and 2 leads to cell cycle blockage and apoptosis via p21Waf1/Cip1 and p19INK4d upregulation in hepatocellular carcinoma. Cell Prolif 2018;51:e12447. [PMID: 29484736 DOI: 10.1111/cpr.12447] [Cited by in Crossref: 35] [Cited by in F6Publishing: 29] [Article Influence: 11.7] [Reference Citation Analysis]
297 Xu H, Xu SJ, Xie SJ, Zhang Y, Yang JH, Zhang WQ, Zheng MN, Zhou H, Qu LH. MicroRNA-122 supports robust innate immunity in hepatocytes by targeting the RTKs/STAT3 signaling pathway. Elife 2019;8:e41159. [PMID: 30735121 DOI: 10.7554/eLife.41159] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
298 Wu D, Jiang H, Yu H, Xu D, Liang J, Jin J. Significant association between XRCC3 C241T polymorphism and increased risk of hepatocellular carcinoma: a meta-analysis. Tumour Biol 2013;34:3865-9. [PMID: 23873110 DOI: 10.1007/s13277-013-0973-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
299 McIntyre CA, Chou JF, Gonen M, Shia J, Gambarin-Gelwan M, Balachandran VP, Kingham TP, Allen PJ, Drebin JA, Jarnagin WR, D'Angelica MI. Hepatocellular carcinoma in patients with no identifiable risk factors. HPB (Oxford) 2021;23:118-26. [PMID: 32591247 DOI: 10.1016/j.hpb.2020.05.005] [Reference Citation Analysis]
300 Chuaypen N, Chittmittraprap S, Pinjaroen N, Sirichindakul B, Poovorawan Y, Tanaka Y, Tangkijvanich P. Serum Wisteria floribunda agglutinin-positive Mac-2 binding protein level as a diagnostic marker of hepatitis B virus-related hepatocellular carcinoma: WFA + -M2BP for diagnosis of HBV-related HCC. Hepatol Res 2018;48:872-81. [DOI: 10.1111/hepr.13187] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
301 Canavese M, Wijesundara D, Maddern GJ, Grubor-Bauk B, Hauben E. Hepatitis C virus drives the pathogenesis of hepatocellular carcinoma: from immune evasion to carcinogenesis. Clin Transl Immunology 2016;5:e101. [PMID: 27867514 DOI: 10.1038/cti.2016.55] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
302 Chen ZY, Guo ZX, Lu LH, Mei J, Lin WP, Li SH, Wei W, Guo RP. The predictive value of vessels encapsulating tumor clusters in treatment optimization for recurrent early-stage hepatocellular carcinoma. Cancer Med 2021;10:5466-74. [PMID: 34212527 DOI: 10.1002/cam4.4102] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
303 Sladky VC, Eichin F, Reiberger T, Villunger A. Polyploidy control in hepatic health and disease. J Hepatol 2021:S0168-8278(21)01879-1. [PMID: 34228992 DOI: 10.1016/j.jhep.2021.06.030] [Reference Citation Analysis]
304 Li MX, Zhao H, Bi XY, Li ZY, Yao XS, Li H, Huang Z, Han Y, Zhou JG, Zhao JJ, Zhang YF, Zhao DB, Cai JQ. Lactate dehydrogenase is a prognostic indicator in patients with hepatocellular carcinoma treated by sorafenib: results from the real life practice in HBV endemic area. Oncotarget 2016;7:86630-47. [PMID: 27880930 DOI: 10.18632/oncotarget.13428] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
305 Finkin S, Yuan D, Stein I, Taniguchi K, Weber A, Unger K, Browning JL, Goossens N, Nakagawa S, Gunasekaran G. Ectopic lymphoid structures function as microniches for tumor progenitor cells in hepatocellular carcinoma. Nat Immunol. 2015;16:1235-1244. [PMID: 26502405 DOI: 10.1038/ni.3290] [Cited by in Crossref: 141] [Cited by in F6Publishing: 130] [Article Influence: 23.5] [Reference Citation Analysis]
306 Hou W, Jin YH, Kang HS, Kim BS. Interleukin-6 (IL-6) and IL-17 synergistically promote viral persistence by inhibiting cellular apoptosis and cytotoxic T cell function.J Virol. 2014;88:8479-8489. [PMID: 24829345 DOI: 10.1128/JVI.00724-14] [Cited by in Crossref: 67] [Cited by in F6Publishing: 46] [Article Influence: 9.6] [Reference Citation Analysis]
307 Ramírez A, Vázquez-Sánchez AY, Carrión-Robalino N, Camacho J. Ion Channels and Oxidative Stress as a Potential Link for the Diagnosis or Treatment of Liver Diseases. Oxid Med Cell Longev 2016;2016:3928714. [PMID: 26881024 DOI: 10.1155/2016/3928714] [Cited by in Crossref: 24] [Cited by in F6Publishing: 18] [Article Influence: 4.8] [Reference Citation Analysis]
308 Qiu J, Zhou Q, Zhang Y, Guan M, Li X, Zou Y, Huang X, Zhao Y, Chen W, Gu X. Discovery of novel quinazolinone derivatives as potential anti-HBV and anti-HCC agents. Eur J Med Chem 2020;205:112581. [PMID: 32791397 DOI: 10.1016/j.ejmech.2020.112581] [Reference Citation Analysis]
309 Zhu H, Xing H, Yu B, Yan W, Zhang C, Guan M, Zhou Y, Wang H, Zhang W, Zhang Y, Li J, Wang Y, Chen T, Zeng Y, Lau WY, Liang L, Li C, Yang T. Long-term survival and recurrence after curative resection for hepatocellular carcinoma in patients with chronic hepatitis C virus infection: a multicenter observational study from China. HPB 2020;22:1793-802. [DOI: 10.1016/j.hpb.2020.04.006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
310 Sun J, Wang J, Zheng D, Hu X. Advances in therapeutic application of CRISPR-Cas9. Brief Funct Genomics 2020;19:164-74. [PMID: 31769791 DOI: 10.1093/bfgp/elz031] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
311 Wachsmann J, Peng F. Molecular imaging and therapy targeting copper metabolism in hepatocellular carcinoma. World J Gastroenterol. 2016;22:221-231. [PMID: 26755872 DOI: 10.3748/wjg.v22.i1.221] [Cited by in CrossRef: 22] [Cited by in F6Publishing: 19] [Article Influence: 5.5] [Reference Citation Analysis]
312 Upadya MH, Aweya JJ, Tan YJ. Understanding the interaction of hepatitis C virus with host DEAD-box RNA helicases. World J Gastroenterol 2014;20:2913-26. [PMID: 24659882 DOI: 10.3748/wjg.v20.i11.2913] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 17] [Article Influence: 3.5] [Reference Citation Analysis]
313 Kiefer RM, Hunt SJ, Pulido S, Pickup S, Furth EE, Soulen MC, Nadolski GJ, Gade TP. Relative Initial Weight Is Associated with Improved Survival without Altering Tumor Latency in a Translational Rat Model of Diethylnitrosamine-Induced Hepatocellular Carcinoma and Transarterial Embolization. J Vasc Interv Radiol 2017;28:1043-1050.e2. [PMID: 28495453 DOI: 10.1016/j.jvir.2017.03.037] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
314 Li S, Li H, Xu X, Saw PE, Zhang L. Nanocarrier-mediated antioxidant delivery for liver diseases. Theranostics 2020;10:1262-80. [PMID: 31938064 DOI: 10.7150/thno.38834] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
315 Yoo SY, Badrinath N, Woo HY, Heo J. Oncolytic Virus-Based Immunotherapies for Hepatocellular Carcinoma. Mediators Inflamm 2017;2017:5198798. [PMID: 28512387 DOI: 10.1155/2017/5198798] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
316 Hao R, He J, Liu X, Gao G, Liu D, Cui L, Yu G, Yu W, Chen Y, Guo D. Inhibition of hepatitis B virus gene expression and replication by hepatocyte nuclear factor 6. J Virol. 2015;89:4345-4355. [PMID: 25653429 DOI: 10.1128/jvi.03094-14] [Cited by in Crossref: 20] [Cited by in F6Publishing: 14] [Article Influence: 3.3] [Reference Citation Analysis]
317 Hassan HA, Serag HM, Qadir MS, Ramadan MF. Cape gooseberry (Physalis peruviana) juice as a modulator agent for hepatocellular carcinoma-linked apoptosis and cell cycle arrest. Biomedicine & Pharmacotherapy 2017;94:1129-37. [DOI: 10.1016/j.biopha.2017.08.014] [Cited by in Crossref: 12] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
318 Umer M, Qureshi SA, Hashmi ZY, Raza A, Ahmad J, Rahman M, Iqbal M. Promoter hypermethylation of Wnt pathway inhibitors in hepatitis C virus - induced multistep hepatocarcinogenesis. Virol J. 2014;11:117. [PMID: 24947038 DOI: 10.1186/1743-422x-11-117] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 2.6] [Reference Citation Analysis]
319 Wang Z, Li Z, Ye Y, Xie L, Li W. Oxidative Stress and Liver Cancer: Etiology and Therapeutic Targets. Oxid Med Cell Longev 2016;2016:7891574. [PMID: 27957239 DOI: 10.1155/2016/7891574] [Cited by in Crossref: 54] [Cited by in F6Publishing: 53] [Article Influence: 10.8] [Reference Citation Analysis]
320 Yi Z, Yuan Z. Hepatitis C Virus-Associated Cancers. Adv Exp Med Biol. 2017;1018:129-146. [PMID: 29052135 DOI: 10.1007/978-981-10-5765-6_8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
321 Bach DH, Lee SK. The Potential Impacts of Tylophora Alkaloids and their Derivatives in Modulating Inflammation, Viral Infections, and Cancer. Curr Med Chem 2019;26:4709-25. [PMID: 30047325 DOI: 10.2174/0929867325666180726123339] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
322 Ringelhan M, Protzer U. Oncogenic potential of hepatitis B virus encoded proteins. Curr Opin Virol 2015;14:109-15. [PMID: 26426688 DOI: 10.1016/j.coviro.2015.08.015] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
323 Matsuzaki K, Seki T, Okazaki K. TGF-β signal shifting between tumor suppression and fibro-carcinogenesis in human chronic liver diseases. J Gastroenterol 2014;49:971-81. [PMID: 24263677 DOI: 10.1007/s00535-013-0910-2] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 2.5] [Reference Citation Analysis]
324 Dang S, Zhou J, Chen Y, Chen P, Ji M, Shi B, Yang Q, Hou P. Dynamic expression of ZNF382 and its tumor-suppressor role in hepatitis B virus-related hepatocellular carcinogenesis. Oncogene 2019;38:4804-19. [PMID: 30804458 DOI: 10.1038/s41388-019-0759-9] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 6.5] [Reference Citation Analysis]
325 Chang TS, Chang KC, Chen WM, Hsu NT, Lee CY, Lin YC, Huang WC, Chiu WN, Hu JH, Huang TJ, Chen MY, Lu SN. Village-to-village screening for hepatitis B and C using quantitative HBsAg and anti-HCV testing with reflex HCV core antigen tests in the remote communities of a resource-rich setting: a population-based prospective cohort study. BMJ Open 2021;11:e046115. [PMID: 34233977 DOI: 10.1136/bmjopen-2020-046115] [Reference Citation Analysis]
326 Yao S, Ye J, Yin M, Yu R. DMAMCL exerts antitumor effects on hepatocellular carcinoma both in vitro and in vivo. Cancer Lett 2020;483:87-97. [PMID: 32268165 DOI: 10.1016/j.canlet.2020.04.003] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 10.0] [Reference Citation Analysis]
327 Lin CW, Chen YS, Lin CC, Lee PH, Lo GH, Hsu CC, Hsieh PM, Koh KW, Bair MJ, Dai CY, Huang JF, Chuang WL, Chen YL, Yu ML. Significant predictors of overall survival in patients with hepatocellular carcinoma after surgical resection. PLoS One 2018;13:e0202650. [PMID: 30180193 DOI: 10.1371/journal.pone.0202650] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
328 Zhou JJ, Meng Z, He XY, Cheng D, Ye HL, Deng XG, Chen RF. Hepatitis C virus core protein increases Snail expression and induces epithelial-mesenchymal transition through the signal transducer and activator of transcription 3 pathway in hepatoma cells. Hepatol Res 2017;47:574-83. [PMID: 27381678 DOI: 10.1111/hepr.12771] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
329 Cho HK, Kim SY, Kyaw YY, Win AA, Koo SH, Kim HH, Cheong J. HBx induces the proliferation of hepatocellular carcinoma cells via AP1 over-expressed as a result of ER stress. Biochem J. 2015;466:115-121. [PMID: 25428452 DOI: 10.1042/bj20140819] [Cited by in Crossref: 20] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
330 Chen Y, Zhao ZX, Huang F, Yuan XW, Deng L, Tang D. MicroRNA-1271 functions as a potential tumor suppressor in hepatitis B virus-associated hepatocellular carcinoma through the AMPK signaling pathway by binding to CCNA1. J Cell Physiol. 2019;234:3555-3569. [PMID: 30565670 DOI: 10.1002/jcp.26955] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 4.3] [Reference Citation Analysis]
331 Utsunomiya T, Shimada M, Kudo M, Ichida T, Matsui O, Izumi N, Matsuyama Y, Sakamoto M, Nakashima O, Ku Y. A comparison of the surgical outcomes among patients with HBV-positive, HCV-positive, and non-B non-C hepatocellular carcinoma: a nationwide study of 11,950 patients. Ann Surg. 2015;261:513-520. [PMID: 25072437 DOI: 10.1097/sla.0000000000000821] [Cited by in Crossref: 78] [Cited by in F6Publishing: 37] [Article Influence: 13.0] [Reference Citation Analysis]
332 Wang K. Molecular mechanisms of liver injury: apoptosis or necrosis. Exp Toxicol Pathol. 2014;66:351-356. [PMID: 24867271 DOI: 10.1016/j.etp.2014.04.004] [Cited by in Crossref: 44] [Cited by in F6Publishing: 39] [Article Influence: 6.3] [Reference Citation Analysis]
333 Hsiao YW, Chiu LT, Chen CH, Shih WL, Lu TP. Tumor-Infiltrating Leukocyte Composition and Prognostic Power in Hepatitis B- and Hepatitis C-Related Hepatocellular Carcinomas. Genes (Basel) 2019;10:E630. [PMID: 31434354 DOI: 10.3390/genes10080630] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
334 Kanaan H, Kourie HR, Awada AH. Are virus-induced cancers more sensitive to checkpoint inhibitors? Future Oncology 2016;12:2665-8. [DOI: 10.2217/fon-2016-0283] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
335 Xue R, Li R, Guo H, Guo L, Su Z, Ni X, Qi L, Zhang T, Li Q, Zhang Z, Xie XS, Bai F, Zhang N. Variable Intra-Tumor Genomic Heterogeneity of Multiple Lesions in Patients With Hepatocellular Carcinoma. Gastroenterology. 2016;150:998-1008. [PMID: 26752112 DOI: 10.1053/j.gastro.2015.12.033] [Cited by in Crossref: 105] [Cited by in F6Publishing: 102] [Article Influence: 21.0] [Reference Citation Analysis]
336 Li Y, Shi F, Hu J, Xie L, Bode AM, Cao Y. The Role of Deubiquitinases in Oncovirus and Host Interactions. J Oncol 2019;2019:2128410. [PMID: 31396277 DOI: 10.1155/2019/2128410] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
337 Wang Q, Lin L, Yoo S, Wang W, Blank S, Fiel MI, Kadri H, Luan W, Warren L, Zhu J, Hiotis SP. Impact of non-neoplastic vs intratumoural hepatitis B viral DNA and replication on hepatocellular carcinoma recurrence. Br J Cancer 2016;115:841-7. [PMID: 27537392 DOI: 10.1038/bjc.2016.239] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
338 Hesketh RL, Zhu AX, Oklu R. Radiomics and circulating tumor cells: personalized care in hepatocellular carcinoma? Diagn Interv Radiol 2015;21:78-84. [PMID: 25430530 DOI: 10.5152/dir.2014.14237] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
339 Huang F, Chen J, Lan R, Wang Z, Chen R, Lin J, Fu L. Hypoxia induced δ-Catenin to enhance mice hepatocellular carcinoma progression via Wnt signaling. Exp Cell Res 2019;374:94-103. [PMID: 30458179 DOI: 10.1016/j.yexcr.2018.11.011] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
340 Yamaguchi T, Yoshida K, Murata M, Matsuzaki K. Smad3 phospho-isoform signaling in hepatitis C virus-related chronic liver diseases. World J Gastroenterol 2014;20:12381-90. [PMID: 25253939 DOI: 10.3748/wjg.v20.i35.12381] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
341 de Almeida NAA, Ribeiro CRA, Raposo JV, de Paula VS. Immunotherapy and Gene Therapy for Oncoviruses Infections: A Review. Viruses 2021;13:822. [PMID: 34063186 DOI: 10.3390/v13050822] [Reference Citation Analysis]
342 Li JQ, Yu XJ, Wang YC, Huang LY, Liu CQ, Zheng L, Fang YJ, Xu J. Distinct patterns and prognostic values of tumor-infiltrating macrophages in hepatocellular carcinoma and gastric cancer. J Transl Med 2017;15:37. [PMID: 28202073 DOI: 10.1186/s12967-017-1139-2] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
343 Muñoz de Rueda P, Fuentes Rodríguez JM, Quiles Pérez R, Gila Medina A, Martín Álvarez AB, Casado Ruíz J, Ruíz Extremera A, Salmerón J. Hepatitis C virus NS5A region mutation in chronic hepatitis C genotype 1 patients who are non-responders to two or more treatments and its relationship with response to a new treatment. World J Gastroenterol 2017;23:4538-47. [PMID: 28740342 DOI: 10.3748/wjg.v23.i25.4538] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.7] [Reference Citation Analysis]
344 Zhang D, Liu H, Lin J, Ye D. Hepatitis B Virus Infection Dampens CtIP Expression in Hepatoma Cell. J Cancer 2018;9:1182-7. [PMID: 29675099 DOI: 10.7150/jca.23649] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
345 Vinciguerra M, Mazzoccoli G, Piccoli C, Tataranni T, Andriulli A, Pazienza V. Exploitation of host clock gene machinery by hepatitis viruses B and C. World J Gastroenterol 2013;19:8902-9. [PMID: 24379614 DOI: 10.3748/wjg.v19.i47.8902] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
346 Liu J, Chen S, Zou Z, Tan D, Liu X, Wang X. Pathological Pattern of Intrahepatic HBV in HCC is Phenocopied by PDX-Derived Mice: a Novel Model for Antiviral Treatment. Transl Oncol 2019;12:1138-46. [PMID: 31202090 DOI: 10.1016/j.tranon.2019.05.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
347 Tao R, Hu S, Wang S, Zhou X, Zhang Q, Wang C, Zhao X, Zhou W, Zhang S, Li C, Zhao H, He Y, Zhu S, Xu J, Jiang Y, Li L, Gao Y. Association between indel polymorphism in the promoter region of lncRNA GAS5 and the risk of hepatocellular carcinoma. Carcinogenesis 2015;36:1136-43. [PMID: 26163879 DOI: 10.1093/carcin/bgv099] [Cited by in Crossref: 71] [Cited by in F6Publishing: 68] [Article Influence: 11.8] [Reference Citation Analysis]
348 Barthel SR, Medvedev R, Heinrich T, Büchner SM, Kettern N, Hildt E. Hepatitis B virus inhibits insulin receptor signaling and impairs liver regeneration via intracellular retention of the insulin receptor. Cell Mol Life Sci 2016;73:4121-40. [PMID: 27155659 DOI: 10.1007/s00018-016-2259-1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
349 Fallahi E, O'Driscoll NA, Matallanas D. The MST/Hippo Pathway and Cell Death: A Non-Canonical Affair. Genes (Basel) 2016;7:E28. [PMID: 27322327 DOI: 10.3390/genes7060028] [Cited by in Crossref: 37] [Cited by in F6Publishing: 30] [Article Influence: 7.4] [Reference Citation Analysis]
350 Okimoto K, Ogasawara S, Chiba T, Kanai F, Yokota H, Motoyama T, Suzuki E, Ooka Y, Tawada A, Iwadate Y. Successful resection of intracranial metastasis of hepatocellular carcinoma. Case Rep Gastroenterol. 2013;7:182-187. [PMID: 23626520 DOI: 10.1159/000350673] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
351 Duan M, Wang ZC, Wang XY, Shi JY, Yang LX, Ding ZB, Gao Q, Zhou J, Fan J. TREM-1, an Inflammatory Modulator, is Expressed in Hepatocellular Carcinoma Cells and Significantly Promotes Tumor Progression. Ann Surg Oncol. 2015;22:3121-3129. [PMID: 25465376 DOI: 10.1245/s10434-014-4191-7] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 4.0] [Reference Citation Analysis]
352 Schinzari V, Barnaba V, Piconese S. Chronic hepatitis B virus and hepatitis C virus infections and cancer: synergy between viral and host factors. Clin Microbiol Infect 2015;21:969-74. [PMID: 26163104 DOI: 10.1016/j.cmi.2015.06.026] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 3.2] [Reference Citation Analysis]
353 Kuo CY, Chou TY, Chen CM, Tsai YF, Hwang GY, Hwang TL. Hepatitis B virus X protein disrupts stress fiber formation and triggers apoptosis. Virus Res 2013;175:20-9. [PMID: 23591626 DOI: 10.1016/j.virusres.2013.03.017] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
354 Chen Y, Xu Y, Zhao M, Liu Y, Gong M, Xie C, Wu H, Wang Z. High-throughput T cell receptor sequencing reveals distinct repertoires between tumor and adjacent non-tumor tissues in HBV-associated HCC. Oncoimmunology 2016;5:e1219010. [PMID: 27853640 DOI: 10.1080/2162402X.2016.1219010] [Cited by in Crossref: 32] [Cited by in F6Publishing: 19] [Article Influence: 6.4] [Reference Citation Analysis]
355 Meng Z, Ma X, Du J, Wang X, He M, Gu Y, Zhang J, Han W, Fang Z, Gan X, Van Ness C, Fu X, Schones DE, Xu R, Huang W. CAMK2γ antagonizes mTORC1 activation during hepatocarcinogenesis. Oncogene 2017;36:2446-56. [PMID: 27819676 DOI: 10.1038/onc.2016.400] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
356 Xu T, Huang Z, Deng Y, Wang S, Su B, Wei W, Wang D, Jiang J, Li A, Zhang G, Yang H, Claret FX, Hu W. Clinical implications of hepatitis B viral infection in Epstein-Barr virus-associated nasopharyngeal carcinoma. J Clin Virol 2015;64:64-71. [PMID: 25728081 DOI: 10.1016/j.jcv.2014.11.024] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
357 Kennedy K, Graham SM, Arora N, Shuhart MC, Kim HN. Hepatocellular carcinoma among US and non-US-born patients with chronic hepatitis B: Risk factors and age at diagnosis. PLoS One 2018;13:e0204031. [PMID: 30252863 DOI: 10.1371/journal.pone.0204031] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
358 Shen J, Huang CK, Yu H, Shen B, Zhang Y, Liang Y, Li Z, Feng X, Zhao J, Duan L, Cai X. The role of exosomes in hepatitis, liver cirrhosis and hepatocellular carcinoma. J Cell Mol Med 2017;21:986-92. [PMID: 28224705 DOI: 10.1111/jcmm.12950] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 7.5] [Reference Citation Analysis]
359 Li Z, Guan M, Lin Y, Cui X, Zhang Y, Zhao Z, Zhu J. Aberrant Lipid Metabolism in Hepatocellular Carcinoma Revealed by Liver Lipidomics. Int J Mol Sci 2017;18:E2550. [PMID: 29182572 DOI: 10.3390/ijms18122550] [Cited by in Crossref: 36] [Cited by in F6Publishing: 32] [Article Influence: 9.0] [Reference Citation Analysis]
360 Li H, Li T, Crispe IN, Tu Z. HCV immune evasion and regulatory T cell activation: cause or consequence? Cell Mol Immunol 2018;15:536-8. [PMID: 29176743 DOI: 10.1038/cmi.2017.131] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
361 Charostad J, Astani A, Goudarzi H, Faghihloo E. DNA methyltransferases in virus-associated cancers. Rev Med Virol 2019;29:e2022. [PMID: 30511446 DOI: 10.1002/rmv.2022] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
362 Jiang H, Ning G, Wang Y, Lv W. Identification of an m6A-Related Signature as Biomarker for Hepatocellular Carcinoma Prognosis and Correlates with Sorafenib and Anti-PD-1 Immunotherapy Treatment Response. Dis Markers 2021;2021:5576683. [PMID: 34221187 DOI: 10.1155/2021/5576683] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
363 Pietropaolo V, Prezioso C, Moens U. Role of Virus-Induced Host Cell Epigenetic Changes in Cancer. Int J Mol Sci 2021;22:8346. [PMID: 34361112 DOI: 10.3390/ijms22158346] [Reference Citation Analysis]
364 Liu L, Zhu J, Yang J, Li X, Yuan J, Wu J, Liu Z. GP73 facilitates hepatitis B virus replication by repressing the NF-κB signaling pathway. J Med Virol 2020. [PMID: 32077512 DOI: 10.1002/jmv.25718] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
365 Jindal A, Thadi A, Shailubhai K. Hepatocellular Carcinoma: Etiology and Current and Future Drugs. J Clin Exp Hepatol 2019;9:221-32. [PMID: 31024205 DOI: 10.1016/j.jceh.2019.01.004] [Cited by in Crossref: 62] [Cited by in F6Publishing: 55] [Article Influence: 31.0] [Reference Citation Analysis]
366 Wang H, Chen XZ, Chen XL, Zhang WH, Liu K, Wang YJ, Tang HR, Hu JK; SIGES research group. Associations between hepatitis B virus exposure and the risk of extrahepatic digestive system cancers: A hospital-based, case-control study (SIGES). Cancer Med 2021;10:3741-55. [PMID: 33934530 DOI: 10.1002/cam4.3901] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
367 Song H, Pan J, Liu Y, Wen H, Wang L, Cui J, Liu Y, Hu B, Yao Z, Ji G. Increased ARPP-19 expression is associated with hepatocellular carcinoma. Int J Mol Sci 2014;16:178-92. [PMID: 25547487 DOI: 10.3390/ijms16010178] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 1.9] [Reference Citation Analysis]
368 Gao W, Jia Z, Tian Y, Yang P, Sun H, Wang C, Ding Y, Zhang M, Zhang Y, Yang D, Tian Z, Zhou J, Ruan Z, Wu Y, Ni B. HBx Protein Contributes to Liver Carcinogenesis by H3K4me3 Modification Through Stabilizing WD Repeat Domain 5 Protein. Hepatology. 2020;71:1678-1695. [PMID: 31544250 DOI: 10.1002/hep.30947] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 15.0] [Reference Citation Analysis]
369 Trierweiler C, Hockenjos B, Zatloukal K, Thimme R, Blum HE, Wagner EF, Hasselblatt P. The transcription factor c-JUN/AP-1 promotes HBV-related liver tumorigenesis in mice. Cell Death Differ 2016;23:576-82. [PMID: 26470729 DOI: 10.1038/cdd.2015.121] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 4.2] [Reference Citation Analysis]
370 McBrearty N, Arzumanyan A, Bichenkov E, Merali S, Merali C, Feitelson M. Short chain fatty acids delay the development of hepatocellular carcinoma in HBx transgenic mice. Neoplasia 2021;23:529-38. [PMID: 33945993 DOI: 10.1016/j.neo.2021.04.004] [Reference Citation Analysis]
371 Chen Y, E CY, Gong ZW, Liu S, Wang ZX, Yang YS, Zhang XW. Chimeric antigen receptor-engineered T-cell therapy for liver cancer. Hepatobiliary Pancreat Dis Int. 2018;17:301-309. [PMID: 29861325 DOI: 10.1016/j.hbpd.2018.05.005] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 10.7] [Reference Citation Analysis]
372 Lin Y, Zhu S, Hu C, Wang J, Jiang P, Zhu L, Li Z, Wang S, Zhang Y, Xu X, Pan W. Cross-Species Suppression of Hepatoma Cell Growth and Migration by a Schistosoma japonicum MicroRNA. Mol Ther Nucleic Acids 2019;18:400-12. [PMID: 31655260 DOI: 10.1016/j.omtn.2019.09.006] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
373 Li M, Wang Y, Xia X, Mo P, Xu J, Yu C, Li W. Steroid receptor coactivator 3 inhibits hepatitis B virus gene expression through activating Akt signaling to prevent HNF4α nuclear translocation. Cell Biosci 2019;9:64. [PMID: 31417670 DOI: 10.1186/s13578-019-0328-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
374 Soppe JA, Lebbink RJ. Antiviral Goes Viral: Harnessing CRISPR/Cas9 to Combat Viruses in Humans. Trends in Microbiology 2017;25:833-50. [DOI: 10.1016/j.tim.2017.04.005] [Cited by in Crossref: 45] [Cited by in F6Publishing: 36] [Article Influence: 11.3] [Reference Citation Analysis]
375 Gao P, Lazare C, Cao C, Meng Y, Wu P, Zhi W, Lin S, Wei J, Huang X, Xi L, Chen G, Hu J, Ma D, Wu P. Immune checkpoint inhibitors in the treatment of virus-associated cancers. J Hematol Oncol 2019;12:58. [PMID: 31182108 DOI: 10.1186/s13045-019-0743-4] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 9.0] [Reference Citation Analysis]
376 Liu XN, Cui DN, Li YF, Liu YH, Liu G, Liu L. Multiple "Omics" data-based biomarker screening for hepatocellular carcinoma diagnosis. World J Gastroenterol. 2019;25:4199-4212. [PMID: 31435173 DOI: 10.3748/wjg.v25.i30.4199] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 16] [Article Influence: 15.0] [Reference Citation Analysis]
377 Kadri H, Blank S, Wang Q, Kim K, Fiel M, Luan W, Hiotis S. Outcomes following liver resection and clinical pathologic characteristics of hepatocellular carcinoma occurring in patients with chronic hepatitis B and minimally fibrotic liver. European Journal of Surgical Oncology (EJSO) 2013;39:1371-6. [DOI: 10.1016/j.ejso.2013.09.029] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
378 Lee S, Mardinoglu A, Zhang C, Lee D, Nielsen J. Dysregulated signaling hubs of liver lipid metabolism reveal hepatocellular carcinoma pathogenesis. Nucleic Acids Res. 2016;44:5529-5539. [PMID: 27216817 DOI: 10.1093/nar/gkw462] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 5.6] [Reference Citation Analysis]
379 Xie D, Zhu WF, Cheng H, Yao ZY, Li M, Zhao YL. An antibody-free assay for simultaneous capture and detection of glycoproteins by surface enhanced Raman spectroscopy. Phys Chem Chem Phys 2018;20:8881-6. [DOI: 10.1039/c7cp08478a] [Cited by in Crossref: 14] [Cited by in F6Publishing: 1] [Article Influence: 4.7] [Reference Citation Analysis]
380 Teng YC, Shen ZQ, Kao CH, Tsai TF. Hepatocellular carcinoma mouse models: Hepatitis B virus-associated hepatocarcinogenesis and haploinsufficient tumor suppressor genes. World J Gastroenterol 2016;22:300-25. [PMID: 26755878 DOI: 10.3748/wjg.v22.i1.300] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
381 Zhu H, Zhang Y, Liu H, Zhang Y, Kang Y, Mao R, Yang F, Zhou D, Zhang J. Preserved Function of Circulating Invariant Natural Killer T Cells in Patients With Chronic Hepatitis B Virus Infection. Medicine (Baltimore). 2015;94:e961. [PMID: 26091463 DOI: 10.1097/md.0000000000000961] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
382 Xie N, Chen X, Zhang T, Liu B, Huang C. Using proteomics to identify the HBx interactome in hepatitis B virus: how can this inform the clinic? Expert Rev Proteomics. 2014;11:59-74. [PMID: 24308553 DOI: 10.1586/14789450.2014.861745] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
383 Deng YR, Yoshida K, Jin QL, Murata M, Yamaguchi T, Tsuneyama K, Moritoki Y, Niu JQ, Matsuzaki K, Lian ZX. Reversible phospho-Smad3 signalling between tumour suppression and fibrocarcinogenesis in chronic hepatitis B infection. Clin Exp Immunol 2014;176:102-11. [PMID: 24372395 DOI: 10.1111/cei.12259] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
384 Lin KR, Deng FW, Jin YB, Chen XP, Pan YM, Cui JH, You ZX, Chen HW, Luo W. T cell receptor repertoire profiling predicts the prognosis of HBV-associated hepatocellular carcinoma. Cancer Med 2018;7:3755-62. [PMID: 29947152 DOI: 10.1002/cam4.1610] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
385 Wang H, Cao H, Xu Z, Wang D, Zeng Y. SNP rs2596542G>A in MICA is associated with risk of hepatocellular carcinoma: a meta-analysis. Biosci Rep. 2019;39. [PMID: 30967497 DOI: 10.1042/bsr20181400] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
386 Luangsay S, Gruffaz M, Isorce N, Testoni B, Michelet M, Faure-Dupuy S, Maadadi S, Ait-Goughoulte M, Parent R, Rivoire M, Javanbakht H, Lucifora J, Durantel D, Zoulim F. Early inhibition of hepatocyte innate responses by hepatitis B virus. J Hepatol. 2015;63:1314-1322. [PMID: 26216533 DOI: 10.1016/j.jhep.2015.07.014] [Cited by in Crossref: 80] [Cited by in F6Publishing: 73] [Article Influence: 13.3] [Reference Citation Analysis]
387 Wang Q, Blank S, Fiel MI, Kadri H, Luan W, Warren L, Zhu A, Deaderick PA, Sarpel U, Labow DM, Hiotis SP. The Severity of Liver Fibrosis Influences the Prognostic Value of Inflammation-Based Scores in Hepatitis B-Associated Hepatocellular Carcinoma. Ann Surg Oncol 2015;22 Suppl 3:S1125-32. [PMID: 26159441 DOI: 10.1245/s10434-015-4598-9] [Cited by in Crossref: 18] [Cited by in F6Publishing: 25] [Article Influence: 3.0] [Reference Citation Analysis]
388 Peng H, Ishida M, Li L, Saito A, Kamiya A, Hamilton JP, Fu R, Olaru AV, An F, Popescu I, Iacob R, Dima S, Alexandrescu ST, Grigorie R, Nastase A, Berindan-Neagoe I, Tomuleasa C, Graur F, Zaharia F, Torbenson MS, Mezey E, Lu M, Selaru FM. Pseudogene INTS6P1 regulates its cognate gene INTS6 through competitive binding of miR-17-5p in hepatocellular carcinoma. Oncotarget 2015;6:5666-77. [PMID: 25686840 DOI: 10.18632/oncotarget.3290] [Cited by in Crossref: 40] [Cited by in F6Publishing: 42] [Article Influence: 8.0] [Reference Citation Analysis]
389 Yong KSM, Her Z, Chen Q. Humanized Mouse Models for the Study of Hepatitis C and Host Interactions. Cells 2019;8:E604. [PMID: 31213010 DOI: 10.3390/cells8060604] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
390 Tarocchi M, Polvani S, Marroncini G, Galli A. Molecular mechanism of hepatitis B virus-induced hepatocarcinogenesis. World J Gastroenterol. 2014;20:11630-11640. [PMID: 25206269 DOI: 10.3748/wjg.v20.i33.11630] [Cited by in CrossRef: 98] [Cited by in F6Publishing: 79] [Article Influence: 16.3] [Reference Citation Analysis]
391 Chen ZY, Wei W, Guo ZX, Peng LX, Shi M, Li SH, Xiao CZ, Zhong C, Qian CN, Guo RP. Using multiple cytokines to predict hepatocellular carcinoma recurrence in two patient cohorts. Br J Cancer 2014;110:733-40. [PMID: 24495874 DOI: 10.1038/bjc.2013.781] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
392 Peng Q, Li S, Lao X, Chen Z, Li R, Qin X. Association between XPD Lys751Gln and Asp312Asn polymorphisms and hepatocellular carcinoma risk: a systematic review and meta-analysis. Medicine (Baltimore) 2014;93:e330. [PMID: 25546681 DOI: 10.1097/MD.0000000000000330] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
393 Liu YP, Yao CY. Rapid and quantitative detection of hepatitis B virus. World J Gastroenterol 2015;21:11954-63. [PMID: 26576084 DOI: 10.3748/wjg.v21.i42.11954] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 18] [Article Influence: 3.8] [Reference Citation Analysis]
394 Yuan X, Wang B, Yang L, Zhang Y. The role of ROS-induced autophagy in hepatocellular carcinoma. Clin Res Hepatol Gastroenterol 2018;42:306-12. [PMID: 29544680 DOI: 10.1016/j.clinre.2018.01.005] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 7.7] [Reference Citation Analysis]
395 Chen XW, Zhou SF. Inflammation, cytokines, the IL-17/IL-6/STAT3/NF-κB axis, and tumorigenesis. Drug Des Devel Ther 2015;9:2941-6. [PMID: 26089643 DOI: 10.2147/DDDT.S86396] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
396 Ben Ari Z, Weitzman E, Safran M. Oncogenic Viruses and Hepatocellular Carcinoma. Clinics in Liver Disease 2015;19:341-60. [DOI: 10.1016/j.cld.2015.01.006] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
397 van de Garde MD, Movita D, van der Heide M, Herschke F, De Jonghe S, Gama L, Boonstra A, Vanwolleghem T. Liver Monocytes and Kupffer Cells Remain Transcriptionally Distinct during Chronic Viral Infection. PLoS One 2016;11:e0166094. [PMID: 27812182 DOI: 10.1371/journal.pone.0166094] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
398 Yuan Z, Ye X, Zhu L, Zhang N, An Z, Zheng WJ. Virome assembly and annotation in brain tissue based on next-generation sequencing. Cancer Med 2020;9:6776-90. [PMID: 32738030 DOI: 10.1002/cam4.3325] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
399 El-Maksoud MA, Habeeb MR, Ghazy HF, Nomir MM, Elalfy H, Abed S, Zaki MES. Clinicopathological study of occult hepatitis B virus infection in hepatitis C virus-associated hepatocellular carcinoma. Eur J Gastroenterol Hepatol. 2019;31:716-722. [PMID: 30870221 DOI: 10.1097/meg.0000000000001388] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 6.0] [Reference Citation Analysis]
400 Wu L, Yang Z, Zhang J, Xie H, Zhou L, Zheng S. Long noncoding RNA HOTTIP expression predicts tumor recurrence in hepatocellular carcinoma patients following liver transplantation. Hepatobiliary Surg Nutr 2018;7:429-39. [PMID: 30652087 DOI: 10.21037/hbsn.2018.10.07] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
401 Hu B, Yu L, Zhu N, Xie J. Cellular UAP56 interacts with the HBx protein of the hepatitis B virus and is involved in viral RNA nuclear export in hepatocytes. Experimental Cell Research 2020;390:111929. [DOI: 10.1016/j.yexcr.2020.111929] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
402 Zhang C, Li J, Huang T, Duan S, Dai D, Jiang D, Sui X, Li D, Chen Y, Ding F. Meta-analysis of DNA methylation biomarkers in hepatocellular carcinoma. Oncotarget. 2016;7:81255-81267. [PMID: 27835605 DOI: 10.18632/oncotarget.13221] [Cited by in Crossref: 40] [Cited by in F6Publishing: 37] [Article Influence: 13.3] [Reference Citation Analysis]
403 Jiang E, Shangguan AJ, Chen S, Tang L, Zhao S, Yu Z. The progress and prospects of routine prophylactic antiviral treatment in hepatitis B-related hepatocellular carcinoma. Cancer Lett 2016;379:262-7. [PMID: 26272181 DOI: 10.1016/j.canlet.2015.07.016] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
404 Dong Z, Yao M, Wang L, Yan X, Gu X, Shi Y, Yao N, Qiu L, Wu W, Yao D. Abnormal expression of insulin-like growth factor-I receptor in hepatoma tissue and its inhibition to promote apoptosis of tumor cells. Tumour Biol. 2013;34:3397-3405. [PMID: 23797814 DOI: 10.1007/s13277-013-0912-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
405 Moens U, Van Ghelue M, Ehlers B. Are human polyomaviruses co-factors for cancers induced by other oncoviruses? Rev Med Virol. 2014;24:343-360. [PMID: 24888895 DOI: 10.1002/rmv.1798] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 3.1] [Reference Citation Analysis]
406 Takaki A, Kawano S, Uchida D, Takahara M, Hiraoka S, Okada H. Paradoxical Roles of Oxidative Stress Response in the Digestive System before and after Carcinogenesis. Cancers (Basel) 2019;11:E213. [PMID: 30781816 DOI: 10.3390/cancers11020213] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 5.5] [Reference Citation Analysis]
407 Miao Z, Zhang S, Ou X, Li S, Ma Z, Wang W, Peppelenbosch MP, Liu J, Pan Q. Estimating the Global Prevalence, Disease Progression, and Clinical Outcome of Hepatitis Delta Virus Infection. J Infect Dis. 2020;221:1677-1687. [PMID: 31778167 DOI: 10.1093/infdis/jiz633] [Cited by in Crossref: 39] [Cited by in F6Publishing: 29] [Article Influence: 39.0] [Reference Citation Analysis]
408 Yu J, Huang WL, Xu QG, Zhang L, Sun SH, Zhou WP, Yang F. Overactivated neddylation pathway in human hepatocellular carcinoma. Cancer Med 2018. [PMID: 29846044 DOI: 10.1002/cam4.1578] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 6.7] [Reference Citation Analysis]
409 Ghorbani A, Hadifar S, Salari R, Izadpanah K, Burmistrz M, Afsharifar A, Eskandari MH, Niazi A, Denes CE, Neely GG. A short overview of CRISPR-Cas technology and its application in viral disease control. Transgenic Res 2021;30:221-38. [PMID: 33830423 DOI: 10.1007/s11248-021-00247-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
410 Katoh M. Cardio-miRNAs and onco-miRNAs: circulating miRNA-based diagnostics for non-cancerous and cancerous diseases. Front Cell Dev Biol 2014;2:61. [PMID: 25364765 DOI: 10.3389/fcell.2014.00061] [Cited by in Crossref: 39] [Cited by in F6Publishing: 38] [Article Influence: 5.6] [Reference Citation Analysis]
411 Rajoriya N, Combet C, Zoulim F, Janssen HLA. How viral genetic variants and genotypes influence disease and treatment outcome of chronic hepatitis B. Time for an individualised approach? J Hepatol. 2017;67:1281-1297. [PMID: 28736138 DOI: 10.1016/j.jhep.2017.07.011] [Cited by in Crossref: 67] [Cited by in F6Publishing: 57] [Article Influence: 16.8] [Reference Citation Analysis]
412 Adianti M, Aoki C, Komoto M, Deng L, Shoji I, Wahyuni TS, Lusida MI, Soetjipto, Fuchino H, Kawahara N, Hotta H. Anti-hepatitis C virus compounds obtained from Glycyrrhiza uralensis and other Glycyrrhiza species. Microbiol Immunol 2014;58:180-7. [PMID: 24397541 DOI: 10.1111/1348-0421.12127] [Cited by in Crossref: 70] [Cited by in F6Publishing: 55] [Article Influence: 10.0] [Reference Citation Analysis]
413 Deng B, Yang M, Wang M, Liu Z. Development and validation of 9-long Non-coding RNA signature to predicting survival in hepatocellular carcinoma. Medicine (Baltimore) 2020;99:e20422. [PMID: 32481346 DOI: 10.1097/MD.0000000000020422] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]
414 Wang H, Feng F, Wang XP, Wang RS, Wu Y, Zhu MG, Zhang H, Zhuang ZX. Dendritic cells pulsed with Hsp70 and HBxAg induce specific antitumor immune responses in hepatitis B virus-associated hepatocellular carcinoma. Mol Med Rep 2016;13:1077-82. [PMID: 26647961 DOI: 10.3892/mmr.2015.4654] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
415 Chen BB, Shih IL, Wu CH, Hsu C, Chen CH, Shih TT, Liu KL, Liang PC. Comparison of characteristics and transarterial chemoembolization outcomes in patients with unresectable hepatocellular carcinoma and different viral etiologies. J Vasc Interv Radiol. 2014;25:371-378. [PMID: 24468045 DOI: 10.1016/j.jvir.2013.10.027] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
416 Lui KY, Zhao H, Qiu C, Li C, Zhang Z, Peng H, Fu R, Chen HA, Lu MQ. Integrator complex subunit 6 (INTS6) inhibits hepatocellular carcinoma growth by Wnt pathway and serve as a prognostic marker. BMC Cancer 2017;17:644. [PMID: 28899352 DOI: 10.1186/s12885-017-3628-3] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
417 Pezzuto F, Izzo F, Buonaguro L, Annunziata C, Tatangelo F, Botti G, Buonaguro FM, Tornesello ML. Tumor specific mutations in TERT promoter and CTNNB1 gene in hepatitis B and hepatitis C related hepatocellular carcinoma. Oncotarget. 2016; Epub ahead of print. [PMID: 27276713 DOI: 10.18632/oncotarget.9801] [Cited by in Crossref: 31] [Cited by in F6Publishing: 25] [Article Influence: 10.3] [Reference Citation Analysis]
418 Kishikawa T, Otsuka M, Yoshikawa T, Ohno M, Takata A, Shibata C, Kondo Y, Akanuma M, Yoshida H, Koike K. Regulation of the expression of the liver cancer susceptibility gene MICA by microRNAs. Sci Rep. 2013;3:2739. [PMID: 24061441 DOI: 10.1038/srep02739] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 4.4] [Reference Citation Analysis]
419 Idrissi ME, Hachem H, Koering C, Merle P, Thénoz M, Mortreux F, Wattel E. HBx triggers either cellular senescence or cell proliferation depending on cellular phenotype. J Viral Hepat 2016;23:130-8. [PMID: 26316075 DOI: 10.1111/jvh.12450] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
420 Lawrenczyk A, Kim S, Wen X, Xiong R, Yuan W. Exploring the Therapeutic Potentials of iNKT Cells for Anti-HBV Treatment. Pathogens. 2014;3:563-576. [PMID: 25438012 DOI: 10.3390/pathogens3030563] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
421 Guo J, Wang M, Wang JP, Wu CX. Ubiquitin-conjugating enzyme E2T knockdown suppresses hepatocellular tumorigenesis via inducing cell cycle arrest and apoptosis. World J Gastroenterol 2019;25:6386-403. [PMID: 31798276 DOI: 10.3748/wjg.v25.i43.6386] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
422 Chatterjee R, Mitra A. An overview of effective therapies and recent advances in biomarkers for chronic liver diseases and associated liver cancer. Int Immunopharmacol. 2015;24:335-345. [PMID: 25560752 DOI: 10.1016/j.intimp.2014.12.024] [Cited by in Crossref: 54] [Cited by in F6Publishing: 47] [Article Influence: 9.0] [Reference Citation Analysis]
423 Han Y, Liu X, Wang Y, Wu X, Guan Y, Li H, Chen X, Zhou B, Yuan Q, Ou Y, Wu R, Huang W, Zhang M, Zhang Y, Zhu D, Zhu H, Yang L, Yi X, Huang C, Huang J. Identification of characteristic TRB V usage in HBV-associated HCC by using differential expression profiling analysis. Oncoimmunology. 2015;4:e1021537. [PMID: 26405574 DOI: 10.1080/2162402x.2015.1021537] [Cited by in Crossref: 24] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
424 Fu J, Wang H. Precision diagnosis and treatment of liver cancer in China. Cancer Letters 2018;412:283-8. [DOI: 10.1016/j.canlet.2017.10.008] [Cited by in Crossref: 107] [Cited by in F6Publishing: 89] [Article Influence: 35.7] [Reference Citation Analysis]
425 Lu Y, Duan Y, Xu Q, Zhang L, Chen W, Qu Z, Wu B, Liu W, Shi L, Wu D, Yang Y, Sun D, Chen X. Circulating exosome-derived bona fide long non-coding RNAs predicting the occurrence and metastasis of hepatocellular carcinoma. J Cell Mol Med. 2020;24:1311-1318. [PMID: 31811749 DOI: 10.1111/jcmm.14783] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 9.0] [Reference Citation Analysis]
426 He J, Huang Y, Liu Z, Zhao R, Liu Q, Wei L, Yu X, Li B, Qin Y. Hypomethylation of BORIS is a promising prognostic biomarker in hepatocellular carcinoma. Gene 2017;629:29-34. [DOI: 10.1016/j.gene.2017.07.077] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
427 Zhou Y, Yin Z, Hou B, Yu M, Chen R, Jin H, Jian Z. Expression profiles and prognostic significance of RNA N6-methyladenosine-related genes in patients with hepatocellular carcinoma: evidence from independent datasets. Cancer Manag Res 2019;11:3921-31. [PMID: 31118805 DOI: 10.2147/CMAR.S191565] [Cited by in Crossref: 41] [Cited by in F6Publishing: 32] [Article Influence: 20.5] [Reference Citation Analysis]
428 Wang W, Sun B, Xia Y, Sun S, He C. RNA N6-Methyladenosine-Related Gene Contribute to Clinical Prognostic Impact on Patients With Liver Cancer. Front Genet 2020;11:306. [PMID: 32391046 DOI: 10.3389/fgene.2020.00306] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
429 Singh S, Singh PP, Roberts LR, Sanchez W. Chemopreventive strategies in hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2014;11:45-54. [PMID: 23938452 DOI: 10.1038/nrgastro.2013.143] [Cited by in Crossref: 185] [Cited by in F6Publishing: 161] [Article Influence: 23.1] [Reference Citation Analysis]
430 Ichzan AM, Hwang SH, Cho H, Fang CS, Park S, Kim G, Kim J, Nandhakumar P, Yu B, Jon S, Kim KS, Yang H. Solid-phase recombinase polymerase amplification using an extremely low concentration of a solution primer for sensitive electrochemical detection of hepatitis B viral DNA. Biosens Bioelectron 2021;179:113065. [PMID: 33578116 DOI: 10.1016/j.bios.2021.113065] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
431 Jegal ME, Jung SY, Han YS, Kim YJ. C-terminal truncated HBx reduces doxorubicin cytotoxicity via ABCB1 upregulation in Huh-7 hepatocellular carcinoma cells. BMB Rep 2019;52:330-5. [PMID: 30982500 [PMID: 30982500 DOI: 10.5483/bmbrep.2019.52.5.312] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
432 Yeganeh B, Rezaei Moghadam A, Alizadeh J, Wiechec E, Alavian SM, Hashemi M, Geramizadeh B, Samali A, Bagheri Lankarani K, Post M, Peymani P, Coombs KM, Ghavami S. Hepatitis B and C virus-induced hepatitis: Apoptosis, autophagy, and unfolded protein response. World J Gastroenterol 2015;21:13225-39. [PMID: 26715805 DOI: 10.3748/wjg.v21.i47.13225] [Cited by in CrossRef: 43] [Cited by in F6Publishing: 40] [Article Influence: 10.8] [Reference Citation Analysis]
433 Shindoh J, Hashimoto M, Watanabe G. Surgical approach for hepatitis C virus-related hepatocellular carcinoma. World J Hepatol. 2015;7:70-77. [PMID: 25624998 DOI: 10.4254/wjh.v7.i1.70] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
434 Chen R, Wu JC, Liu T, Qu Y, Lu LG, Xu MY. MicroRNA profile analysis in the liver fibrotic tissues of chronic hepatitis B patients. J Dig Dis. 2017;18:115-124. [PMID: 28127890 DOI: 10.1111/1751-2980.12452] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
435 Colombo M, Lleo A. The impact of antiviral therapy on hepatocellular carcinoma epidemiology. Hepat Oncol 2018;5:HEP03. [PMID: 30302194 DOI: 10.2217/hep-2017-0024] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 3.7] [Reference Citation Analysis]
436 Gigi E, Lagopoulos VI, Bekiari E. Hepatocellular carcinoma occurrence in DAA-treated hepatitis C virus patients: Correlated or incidental? A brief review. World J Hepatol 2018;10:595-602. [PMID: 30310537 DOI: 10.4254/wjh.v10.i9.595] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
437 Manzoor S, Saalim M, Imran M, Resham S, Ashraf J. Hepatitis B virus therapy: What's the future holding for us? World J Gastroenterol. 2015;21:12558-12575. [PMID: 26640332 DOI: 10.3748/wjg.v21.i44.12558] [Cited by in CrossRef: 27] [Cited by in F6Publishing: 24] [Article Influence: 5.4] [Reference Citation Analysis]
438 Chen J, Wu X, Cai B, Su Z, Li L, An Y, Wang L. Circulating microRNAs as potential biomarkers of HBV infection persistence. Infect Genet Evol 2017;54:152-7. [PMID: 28648686 DOI: 10.1016/j.meegid.2017.06.023] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
439 Yuan Y, Panwar N, Yap SHK, Wu Q, Zeng S, Xu J, Tjin SC, Song J, Qu J, Yong K. SERS-based ultrasensitive sensing platform: An insight into design and practical applications. Coordination Chemistry Reviews 2017;337:1-33. [DOI: 10.1016/j.ccr.2017.02.006] [Cited by in Crossref: 53] [Cited by in F6Publishing: 24] [Article Influence: 13.3] [Reference Citation Analysis]
440 Franssen B, Alshebeeb K, Tabrizian P, Marti J, Pierobon ES, Lubezky N, Roayaie S, Florman S, Schwartz ME. Differences in surgical outcomes between hepatitis B- and hepatitis C-related hepatocellular carcinoma: a retrospective analysis of a single North American center. Ann Surg. 2014;260:650-656; discussion 656-658. [PMID: 25203882 DOI: 10.1097/sla.0000000000000917] [Cited by in Crossref: 58] [Cited by in F6Publishing: 24] [Article Influence: 8.3] [Reference Citation Analysis]
441 Zheng H, Jiang WH, Tian T, Tan HS, Chen Y, Qiao GL, Han J, Huang SY, Yang Y, Li S, Wang ZG, Gao R, Ren H, Xing H, Ni JS, Wang LH, Ma LJ, Zhou WP. CBX6 overexpression contributes to tumor progression and is predictive of a poor prognosis in hepatocellular carcinoma. Oncotarget 2017;8:18872-84. [PMID: 28122351 DOI: 10.18632/oncotarget.14770] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 4.8] [Reference Citation Analysis]
442 Sun S, Li Y, Han S, Jia H, Li X, Li X. A comprehensive genome-wide profiling comparison between HBV and HCV infected hepatocellular carcinoma. BMC Med Genomics 2019;12:147. [PMID: 31660973 DOI: 10.1186/s12920-019-0580-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 4.5] [Reference Citation Analysis]
443 Chen Y, Yang W, Chen Q, Liu Q, Liu J, Zhang Y, Li B, Li D, Nan J, Li X, Wu H, Xiang X, Peng Y, Wang J, Su S, Wang Z. Prediction of hepatocellular carcinoma risk in patients with chronic liver disease from dynamic modular networks. J Transl Med 2021;19:122. [PMID: 33757544 DOI: 10.1186/s12967-021-02791-9] [Reference Citation Analysis]
444 An C, Choi YA, Choi D, Paik YH, Ahn SH, Kim MJ, Paik SW, Han KH, Park MS. Growth rate of early-stage hepatocellular carcinoma in patients with chronic liver disease. Clin Mol Hepatol 2015;21:279-86. [PMID: 26523271 DOI: 10.3350/cmh.2015.21.3.279] [Cited by in Crossref: 47] [Cited by in F6Publishing: 40] [Article Influence: 7.8] [Reference Citation Analysis]
445 Ringelhan M, O'Connor T, Protzer U, Heikenwalder M. The direct and indirect roles of HBV in liver cancer: prospective markers for HCC screening and potential therapeutic targets. J Pathol. 2015;235:355-367. [PMID: 25196558 DOI: 10.1002/path.4434] [Cited by in Crossref: 78] [Cited by in F6Publishing: 70] [Article Influence: 13.0] [Reference Citation Analysis]
446 Tsai YC, Li PY, Chen CC, Liu YC. Is the oxidative DNA damage level of human lymphocyte correlated with the antioxidant capacity of serum or the base excision repair activity of lymphocyte? Oxid Med Cell Longev 2013;2013:237583. [PMID: 24349611 DOI: 10.1155/2013/237583] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
447 Shen F, Huang W, Qi JH, Yuan BF, Huang JT, Zhou X, Feng YQ, Liu YJ, Liu SM. Association of 5-methylcytosine and 5-hydroxymethylcytosine with mitochondrial DNA content and clinical and biochemical parameters in hepatocellular carcinoma. PLoS One. 2013;8:e76967. [PMID: 24143196 DOI: 10.1371/journal.pone.0076967] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
448 García-niño WR, Zazueta C. Ellagic acid: Pharmacological activities and molecular mechanisms involved in liver protection. Pharmacological Research 2015;97:84-103. [DOI: 10.1016/j.phrs.2015.04.008] [Cited by in Crossref: 123] [Cited by in F6Publishing: 82] [Article Influence: 20.5] [Reference Citation Analysis]
449 Chen X, Du Y, Hu Q, Huang Z. Tumor-derived CD4+CD25+regulatory T cells inhibit dendritic cells function by CTLA-4. Pathol Res Pract. 2017;213:245-249. [PMID: 28214198 DOI: 10.1016/j.prp.2016.12.008] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
450 Lv X, Ye G, Zhang X, Huang T. p16 Methylation was associated with the development, age, hepatic viruses infection of hepatocellular carcinoma, and p16 expression had a poor survival: A systematic meta-analysis (PRISMA). Medicine (Baltimore) 2017;96:e8106. [PMID: 28930859 DOI: 10.1097/MD.0000000000008106] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 2.8] [Reference Citation Analysis]
451 Antonioli L, Blandizzi C, Pacher P, Haskó G. Immunity, inflammation and cancer: a leading role for adenosine. Nat Rev Cancer 2013;13:842-57. [PMID: 24226193 DOI: 10.1038/nrc3613] [Cited by in Crossref: 415] [Cited by in F6Publishing: 366] [Article Influence: 51.9] [Reference Citation Analysis]
452 Li L, Wang H. Heterogeneity of liver cancer and personalized therapy. Cancer Lett. 2016;379:191-197. [PMID: 26213370 DOI: 10.1016/j.canlet.2015.07.018] [Cited by in Crossref: 78] [Cited by in F6Publishing: 70] [Article Influence: 13.0] [Reference Citation Analysis]
453 Lee H, Kim H, Lee SA, Won YS, Kim HI, Inn KS, Kim BJ. Upregulation of endoplasmic reticulum stress and reactive oxygen species by naturally occurring mutations in hepatitis B virus core antigen. J Gen Virol. 2015;96:1850-1854. [PMID: 25828947 DOI: 10.1099/vir.0.000134] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 2.7] [Reference Citation Analysis]
454 Liao J, Zeng D, Li J, Hua Q, Xiao Z, He C, Mao K, Zhu L, Chu Y, Wen W, Zheng L, Wu Y. Targeting adenosinergic pathway enhances the anti-tumor efficacy of sorafenib in hepatocellular carcinoma. Hepatol Int 2020;14:80-95. [DOI: 10.1007/s12072-019-10003-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
455 Huang G, Li P, Lau WY, Pan Z, Zhao L, Wang Z, Wang M, Zhou W. Antiviral Therapy Reduces Hepatocellular Carcinoma Recurrence in Patients With Low HBV-DNA Levels: A Randomized Controlled Trial. Annals of Surgery 2018;268:943-54. [DOI: 10.1097/sla.0000000000002727] [Cited by in Crossref: 33] [Cited by in F6Publishing: 20] [Article Influence: 11.0] [Reference Citation Analysis]
456 Haron AS, Syed Alwi SS, Saiful Yazan L, Abd Razak R, Ong YS, Zakarial Ansar FH, Roshini Alexander H. Cytotoxic Effect of Thymoquinone-Loaded Nanostructured Lipid Carrier (TQ-NLC) on Liver Cancer Cell Integrated with Hepatitis B Genome, Hep3B. Evid Based Complement Alternat Med 2018;2018:1549805. [PMID: 30186351 DOI: 10.1155/2018/1549805] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
457 Nazzal M, Sur S, Steele R, Khatun M, Patra T, Phillips N, Long J, Ray R, Ray RB. Establishment of a Patient-Derived Xenograft Tumor From Hepatitis C-Associated Liver Cancer and Evaluation of Imatinib Treatment Efficacy. Hepatology 2020;72:379-88. [PMID: 32356575 DOI: 10.1002/hep.31298] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 8.0] [Reference Citation Analysis]
458 Wrighton PJ, Oderberg IM, Goessling W. There Is Something Fishy About Liver Cancer: Zebrafish Models of Hepatocellular Carcinoma. Cell Mol Gastroenterol Hepatol 2019;8:347-63. [PMID: 31108233 DOI: 10.1016/j.jcmgh.2019.05.002] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 8.5] [Reference Citation Analysis]
459 Du L, Zhang B, Lei Y, Wang S, Jin Y. Long-circulating and liver-targeted nanoassemblies of cyclic phosphoryl N -dodecanoyl gemcitabine for the treatment of hepatocellular carcinoma. Biomedicine & Pharmacotherapy 2016;79:208-14. [DOI: 10.1016/j.biopha.2016.02.024] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
460 Soriano V, Sherman KE, Barreiro P. Hepatitis delta and HIV infection. AIDS 2017;31:875-84. [DOI: 10.1097/qad.0000000000001424] [Cited by in Crossref: 18] [Cited by in F6Publishing: 5] [Article Influence: 4.5] [Reference Citation Analysis]
461 He X, Hu X, Jin H, Gan J, Zhu H, Li J, Long Y, Tian H. Quick Serological Detection of a Cancer Biomarker with an Agglutinated Supramolecular Glycoprobe. Anal Chem 2015;87:9078-83. [DOI: 10.1021/acs.analchem.5b02384] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
462 Pandey V, Kumar V. Stabilization of SIRT7 deacetylase by viral oncoprotein HBx leads to inhibition of growth restrictive RPS7 gene and facilitates cellular transformation. Sci Rep. 2015;5:14806. [PMID: 26442981 DOI: 10.1038/srep14806] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
463 Zella D, Gallo RC. Viruses and Bacteria Associated with Cancer: An Overview. Viruses 2021;13:1039. [PMID: 34072757 DOI: 10.3390/v13061039] [Reference Citation Analysis]
464 Zeng T, Wang D, Chen J, Tian Y, Cai X, Peng H, Zhu L, Huang A, Tang H. LncRNA-AF113014 promotes the expression of Egr2 by interaction with miR-20a to inhibit proliferation of hepatocellular carcinoma cells. PLoS One 2017;12:e0177843. [PMID: 28542387 DOI: 10.1371/journal.pone.0177843] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
465 El-mesery M, El-mowafy M, Youssef LF, El-mesery A, Abed SY, Elgaml A. Serum Soluble Fibrinogen-Like Protein 2 Represents a Novel Biomarker for Differentiation Between Acute and Chronic Egyptian Hepatitis B Virus-Infected Patients. Journal of Interferon & Cytokine Research 2021;41:52-9. [DOI: 10.1089/jir.2020.0118] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
466 Wang Q, Luan W, Warren L, Fiel MI, Blank S, Kadri H, Mandeli J, Hiotis SP. Prognostic Role of Immune Cells in Hepatitis B-associated Hepatocellular Carcinoma Following Surgical Resection Depends on Their Localization and Tumor Size. Journal of Immunotherapy 2016;39:36-44. [DOI: 10.1097/cji.0000000000000104] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]